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Abstract 
Mycobacterium tuberculosis (M. tuberculosis), the causative agent of tuberculosis, 
utilizes mycothiol (MSH) as the major low molecular weight thiol to protect itself 
against oxidative stress and thereby to ensure its growth and survival. MSH is a 
pseudo-disaccharide molecule that contains an α(1→1) glycosidic bond, and is 
biosynthesised in five enzymatic steps involving the enzymes MshA, MshA2, MshB, 
MshC and MshD. Owing to the essentiality of MSH to M. tuberculosis, various 
studies have focused on the MSH biosynthetic and other MSH-dependent enzymes 
viewed as potential drug targets for the development of antituberculosis agents. In 
the course of this study two practical challenges affecting the development of 
inhibitors of one the MSH biosynthesis pathway enzyme, MshB, were addressed. 
These challenges entail the lack of a high-throughput continuous assay to determine 
MshB activity, and the poor availability of the natural and alternative MshB 
substrates. In this study an alternate MshB substrate was characterized and shown 
to undergo a rearrangement reaction upon deactylation, which allowed the 
development of a new continuous assay for MshB activity that uses DNTB (Ellman’s 
reagent). In addition, three new α-thioglycoligases were created from the α-N-
acetylglucosaminidase of Clostridium perfringens. These enzymes showed potential 
as biocatalysts that can be used for the enzymatic synthesis of thioglycoside-based 
alternative substrates of MshB.  
 





Mycobacterium tuberculosis, die organisme wat tuberkulose  veroorsaak, maak 
gebruik van mikotiol (MSH) om homself te beskerm teen oksidatiewe stres en 
sodoende sy groei en oorlewing te verseker. MSH is ŉ pseudo-disakkaried molekule 
met ŉ α(1→1) glikosidiese binding, en word in vyf ensimatiese stappe 
gebiosintetiseer deur die ensieme MshA, MshA2, MshB, MshC en MshD. Weens die 
noodsaaklikheid van MSH vir M. tuberculosis het verskeie vorige studies gefokus op 
die MSH biosintetiese en ander MSH-afhanklike ensieme as potensiële teikens vir 
die ontwikkeling van antituberkulose middels. In die loop van hierdie studie is twee 
praktiese uitdagings wat die ontwikkeling van inhibitors van een van die MSH 
biosintetiese ensieme, MshB, bemoeilik, aangespreek. Hierdie uitdagings behels die 
gebrek aan 'n geskikte hoë-deurvloei kontinue essaï vir MshB aktiwiteit, en die lae 
beskikbaarheid van die natuurlike en alternatiewe MshB substrate. In hierdie studie is 
alternatiewe MshB substrate gekarakteriseer en is daar gewys dat dit ŉ 
herrangskikkingsreaksie ondergaan na deasetilering, wat die ontwikkeling van ŉ 
nuwe kontinue essaï vir MshB aktiwiteit wat gebruik maak van DTNB (Ellman se 
reagens), moontlik gemaak het. Verder is drie nuwe α-tioglikoligases ontwikkel van 
die ensiem α-N-asetielglukosaminidase van Clostridium perfringens. Hierdie ensieme 
toon potensiaal as biokataliste wat gebruik kan word in die ensiematiese sintese van 
tioglikosied-gebaseerde alternatiewe substrate van MshB. 
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Chapter 1: Introduction 
1.1 Introduction  
Tuberculosis (TB) is a lethal infectious disease that claims over a million lives per 
year worldwide [1-3]. The causative agent of TB is Mycobacterium tuberculosis, a 
pathogenic actinomycete that was discovered by Robert Koch in 1882 [2]. Although 
infection of a host system by M. tuberculosis can result in an active infection, the 
pathogen is found in a latent form (inactive and non-infectious) in one third of the 
world’s population. This latent infection can develop into active disease as a result of 
several factors such as unhygienic living conditions, diabetes, anti-tumour necrosis 
factor therapy or co-infection with the human immunodeficiency virus (HIV). The 
majority of TB cases are reported in developing countries, owing to poor health care 
facilities and a high number of HIV infections [1]. 
The first anti-TB drug, streptomycin, was discovered in the 1940s by Schatz and 
Waksman [4]. This was followed by the development of other anti-TB drugs including 
isoniazid, rifamycin, ethambutol and pyrazinamide, among others [2, 4]. Isoniazid and 
rifamycin are currently the most effective first-line drugs used to treat drug-
susceptible TB (DS-TB). This treatment involves a four-drug regimen; whereby 
isoniazid, rifamycin, ethambutol and pyrazinamide are used for the first 2-3 months, 
followed by the co-administration of isoniazid and rifamycin for the next 4-6 months 
[2, 3]. Approximately 95% of DS-TB infections are curable, provided that the 
treatment is completed and that the right dosage is taken [2]. 
Incomplete treatment and misuse of drugs (especially pertaining to isoniazid and 
rifamycin) lead to the development of multi-drug-resistant TB (MDR-TB) [2, 5]. To 
treat people infected with MDR-TB second-line drugs are required, which includes 
capreomycin, amikacin and kanamycin. [2, 5]. MDR-TB strain requires a more 
protracted treatment than DS-TB strain, which involves eight to ten-drug regimens. 
Improper use of the second-line drugs or interaction of the anti-TB drugs with other 
drugs, such as antiviral and diabetic drugs, lead to the development of another strain 
of M. tuberculosis known as extensively-drug-resistant TB (XDR-TB). This strain is 
non-susceptible to both the first- and second-line anti-TB drugs [2]. In addition, it has 
the highest mortality rate of the different strains.  
Stellenbosch University  http://scholar.sun.ac.za
2 
The rise in the occurrence of the drug-resistant strains and the failure of the current 
drug regimens to control this rise, highlights the urgent need for the identification of 
new M. tuberculosis drug targets for the development of new treatments against TB. 
In the next section one of these possible drug targets, namely the disruption of redox 
balance, is highlighted. 
1.2 Redox balance as a drug target  
The word “redox” describes two fundamental processes that occur within all living 
organisms, namely reduction and oxidation reactions [6, 7]. Reduction is defined as a 
gain of electrons by the oxidising agent (oxidant), while oxidation is the loss of 
electrons by the reducing agent (reductant) [8, 9]. Maintenance of cellular redox 
balance is crucial to all living organisms [6, 7]. The redox balance is preserved by the 
generation and elimination of reactive species (RS) that includes reactive oxygen 
species (ROS) such as superoxide, hydroxyl, hydrogen peroxide, and reactive 
nitrogen species (RNS) such as nitric oxide and peroxynitrite.  
Upon infection of the human system by M. tuberculosis the pathogen is introduced to 
the innate or adaptive immune mechanism of the host, wherein macrophage 
activating factors, such as gamma-interferon and tumor necrosis factor-alpha, are 
released to activate the macrophage. This in turn releases the RS [1, 10]. The RS 
disrupt the redox balance system of the mycobacterium which results in a condition 
known as oxidative stress–a state in which more reactive species are generated than 
can be eliminated from the cell system [7, 9, 11]. The high concentration of RS leads 
to DNA damage, protein degradation and lipid peroxidation which results in growth 
inhibition or death of the mycobacterium [9, 11, 12]. Therefore, disturbance of the 
redox balance system in this pathogenic microorganism can serve as a potential 
target for the development of new antimicrobials. 
Most organisms use low molecular weight thiol-containing compounds to cope with 
endogenous and exogenous stresses and also to maintain the cellular redox balance 
[13-15]. These compounds are intracellular redox-regulating antioxidants that act 
both as buffer and reducing factors to maintain the intracellular reducing 
environment. A variety of thiol molecules have been identified in various organisms, 
including the cysteinyl pseudo-disaccharide mycothiol (MSH), trypanothione (T[SH]2), 
coenzyme A (CoASH) and the tripeptide glutathione (GSH) (Figure 1.1). Of these 
four molecules GSH, which is the major thiol-containing molecule found in 
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eukaryotes (i.e. humans) and Gram-negative bacteria, is the best studied [14]. In 
contrast, selected Gram-positive bacteria, trypanosomatids and actinomycetes 
exploit CoASH, (T[SH]2) and MSH respectively as their low-molecular weight thiols. 
MSH was first isolated by Newton and co-workers in 1993 from a Streptomycetes cell 
extract [16] and has since been established as the major and most utilized low-
molecular weight thiol in the actinomycetes, which includes M. tuberculosis and 
Mycobacterium smegmatis [17]. Due to its central role in maintaining the redox 
balance in M. tuberculosis, MSH has been identified as a possible drug target for 
antituberculosis drug development. 
 
Fig. 1.1: Examples of different low molecular weight thiols used by various organisms to 
maintain their intracellular redox balance. The thiol group (Shown rectangle) facilitates the 
maintenance of redox balance within the cell [14]. 
1.3 Mycothiol as the low molecular weight thiol of Mycobacterium 
tuberculosis 
MSH consists of two sugar moieties, N-glucosamine and inositol, connected to each 
other by an α(1→1) glycosidic bond (Figure 1.1) [5, 14, 18]. Additionally, the amine 
N-glucosamine is linked to a cysteine (Cys) via an amide bond, while the amine 
group of the Cys is acetylated [5, 15].  
M. tuberculosis produces MSH in millimolar quantities, which can be explained by the 
fact that the most important function of MSH in mycobacteria is to maintain the 
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intracellular redox environment [14, 18-20]. This process is homologous to the role of 
GSH in both eukaryotes and Gram-negative bacteria. Furthermore mycobacteria 
utilize MSH to detoxify xenobiotics (alkylating agents and formaldehyde) and MSH 
can act as a reservoir of cysteine and glucosamine inositol (GlcN-Ins), both of which 
serves as biosynthetic intermediates and as energy sources during stress.  
1.3.1 The mycothiol biosynthesis pathway 
MSH is produced in a biosynthetic pathway that involves five enzyme catalysed steps 
[14, 18, 20]. The first step in the MSH biosynthetic pathway involves the transfer of 
N-acetylglucosamine from UDP-N-acetylglucosamine (UDP-GlcNAc) to 1-L-myo-
inositol-1-phosphate (1-L-Ins-1-P) producing 3-phospho-1-D-myo-inosityl-2-
acetamido-2-deoxy-α-D-glucopyranoside (GlcNAc-Ins-3-P) (Figure 1.2). This step is 
catalyzed by glycosyltransferase (MshA). GlcNAc-Ins-3-P is dephosphorylated by the 
phosphatase (MshA2) to yield GlcNAc-Ins. This is followed by deacetylation by 
GlcNAc-Ins N-deacetylase (MshB) to yield the free amino-sugar, glucosamine-
inositol (GlcN-Ins). Subsequently GlcN-Ins is condensed with Cys, at the cost of one 
ATP molecule, by MSH ligase (MshC), yielding cysteine- glucosamine-inositol (Cys-
GlcN-Ins). The final step in the pathway is catalyzed by MSH synthase (MshD), an 
acetylase that transfers an acetyl group from acetyl-CoA to the free amine group of 
Cys-GlcN-Ins to produce MSH. 
 
Fig. 1.2: The MSH biosynthesis pathway [14, 18, 20].  
 
Stellenbosch University  http://scholar.sun.ac.za
5 
1.3.1.1 MshA and MshA2 
MshA, a retaining glycotransferase, catalyses the transfer of 1-L-Ins-1-P to α-UDP-
GlcNAc to form GlcNAc-(α1,1)-1-D-Ins-3P which has the same anomeric 
configuration as UDP-GlcNAc (Figure 1.2) [14, 18]. The biochemistry of MshA was 
first determined by Newton et al. (2006) [21] using free cell-extract of M. smegmatis, 
wherein they discovered α-UDP-GlcNAc as the substrate donor and 1-L-Ins-1-P as 
the substrate acceptor. However, the first crystal structure of MshA was determined 
by Vetting et al. in 2008 [22] of the Corynebacterium glutamicum homologue, wherein 
they utilised two type of crystal forms: P31 form (APO-enzyme form), binary complex 
of UDP, and I422 form (ternary complex), binary complex of UDP and 1-L-Ins-1-P. 
MshA was found to consist of two domains: N-terminal domain and C-terminal 
domain which display the β/α/β Rossmann-fold type of GT-B fold superfamily with the 
active site flanked by the domains. Furthermore, MshA was proposed to use an SNi 
substrate-assisted mechanism due to the lack of a nucleophile at the active site, 
wherein the binding of UDP-GlcNAc leads to the binding of 1-L-Ins-1-P, upon which 
the hydroxyl group of 1-L-Ins-1-P and β-phosphate of UDP-GlcNAc both act as 
nucleophiles in the reaction to produce GlcNAc-Ins-3-P (Scheme 1.1) [18, 22]. 
Subsequently, MshA2 dephosphorylates GlcNAc-Ins-3-P to give GlcNAc-Ins[14, 21] . 
The identity of MshA2 still remains to be discovered. 
 
Scheme 1.1: The proposed SNi substrate-assisted mechanism of MshA. Scheme 
adapted from Vetting et al. 2008 [22]. 
 
1.3.1.2 MshB 
MshB is a metalloprotein that catalyses the third reaction of the MSH biosynthetic 
pathway [14, 23, 24]. It was identified as the key enzyme in the pathway by Newton 
et al. in 2000 [25] through the discovery of a homologous metalloprotein known as 
mycothiol S-conjugate amidase (Mca). MshB has a high specificity for its natural 
substrate GlcNAc-Ins, a key intermediate within the MSH biosynthetic pathway. 
Inactivation studies of the mshB gene done by Rawat et al. [26] confirmed MshB as 
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the key enzyme in the MSH biosynthetic pathway. In addition, MshB was 
demonstrated to be non-essential for the growth or synthesis of MSH in M. 
tuberculosis, since the mutant strain still produce some MSH. This was attributed to 
its homologous metalloprotein, Mca (Mca will be discussed in more detail in later 
section).  
In the catalytically active site of MshB a Zn2+ cation is coordinated to His13, His147, 
Aps16 and two water molecules.  The presence of the metal ions was confirmed by 
two independent crystallization studies [27, 28]. The first study by Maynes et al. in 
2003 proposed that the catalytic mechanism of MshB is an acid-base mechanism. 
They proposed that His144 acts as the acid and Asp15 as the base [27]. This 
mechanism was confirmed by a study conducted in 2012 by Huang and Herick, in 
which they discovered an additional amino acid, Tyr142, which facilitate the stability of 
the oxanion tetrahedral intermediate (Scheme 1.2) [24]. The binding of MshB to its 
substrate permits the carbonyl oxygen of the acetyl group to replace the water-Zn2+ 
adduct to make way for another water molecule to enter and attack the carbonyl 
carbon of the acetyl group. The attack on the carbonyl carbon by the water molecule 
is facilitated by the carboxylate base of Asp15, while His144 assists with the 
dissociation of the intermediate to give GlcN-Ins.  
 




MshC is a ligase enzyme that ligates cysteine and GlcN-Ins, the MshB reaction 
product, at expense of an ATP molecule [18]. This reaction was discovered in 2002 
by Sareen et al. [29] in a crude extract of M. smegmatis. To date only the MshC of M. 
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smegmatis has been expressed heterologously from E. coli and purified to 
homogeneity. Inhibition studies done by Fan et al. [30] using 5'-O-[N-L-
cysteinyl)sulfamonyl]adenosine (CSA) as the inhibiting compound, showed that the 
ligation reaction of Cys to GlcN-Ins occurs in two steps: first the adenylation of Cys 
followed by the condensation of the Cys to GlcN-Ins. They determined the catalytic 
mechanism of MshC as a Bi Uni Uni Bi Ping Pong mechanism through steady-state 
kinetics and position isotope exchange studies (Scheme 1.3). The binding of ATP 
and Cys to MshC causes the liberation of pyrophosphate (PPi) and the formation of 
the adenylated-Cys intermediate. After binding of the GlcN-Ins to the enzyme, the 
Cys is transferred from the enzyme-AMP complex to the GlcN-Ins and Cys-GlcN-Ins 
and AMP are released from the enzyme.  
 
Scheme 1.3: The catalytic mechanism of MshC. Scheme adapted from Fan et al., 
2009 [18]. 
In an unrelated study, MshC was crystallised bound to CSA revealing a cluster of 
electron density residues, a flexible loop structure and a zinc ion bound to the thiolate 
of the CSA in the active site [31]. The fact that the zinc ion was bound to the thiolate 
of the CSA was taken as evidence that this interaction serves as the basis for the 
amino acid discriminating ability of the protein. 
 
1.3.1.4 MshD 
MshD is an acetyltransferase protein which belongs to the GCN5-related N-
acetlytransferase (GNATs) family [23, 32]. This enzyme catalyse the final reaction in 
the MSH biosynthetic pathway; transferring an acetyl group to Cys-GlcN-Ins to give 
MSH (Figure 1.2).  
The crystal structure of M. tuberculosis MshD has been solved by Vetting et al. [33]. 
The enzyme has been crystallised in a binary complex system with acetyl-CoA 
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(AcCoA) and as a ternary complex with CoA and desacetylmycothiol (DAM) [18, 33, 
34]. MshD contains two GNAT domains, one on the N-terminal side and one on the 
C-terminal side. These domains are linked by a random coil. The domains utilise two 
different to bind to the AcCoA. The C-terminal domain possesses the catalytic activity 
while the N-terminal domain stabilizes the structure of the protein.  
The catalytic mechanism of M. tuberculosis MshD was proposed by Vetting et al. in 
2006 [34]. There are three amino acids important for activity: the glutamic acid at 
position 324 (Glu324), the tyrosine at position 294 (Tyr294) and the leucine at position 
238 (Leu238) (Scheme 1.4). Glu324 and Tyr294 acts as a base and acid respectively, 
while Leu238 stabilises the tetrahedral intermediate [18, 33, 34]. Glu324 coordinates a 
water molecule and abstracts a proton from the free amine group of Cys-GlcN-Ins. 
Tyr294 protonate the sulfhydryl-group of CoA after the acetyl is transferred to form the 

























































Scheme 1.4: The catalytic mechanism of MshD. Scheme adapted from Vetting et al., 
2006 [34]. 
 
1.3.2 Function of mycothiol in M. tuberculosis  
Actinomycetes including M. tuberculosis employ MSH in three different metabolic 
processes: defensive reactions against ROS, RNS and xenobiotic agents; 
degradation reactions during nutrient starvation; and metabolic reactions wherein 
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MSH act as a cofactor for the growth of mycobacteria [15]. All of these reactions are 
catalysed by various MSH-dependent enzymes (Figure 1.3) [14, 15, 35]. The 
defensive reactions are catalysed by mycothiol disulfide reductase (Mtr), mycothiol-
S-nitrosoreductase/-formaldehyde dehydrogenase (MscR), thiol peroxidases and 
Mca. Mca also catalyse the degradation reactions that provide nutrients for the 
mycobacteria. It is the best studied enzyme of these pathways, as it has been 
identified and assayed first [14, 23]. The metabolic reactions are catalysed by 
maleylpyruvate isomerase.  
Fig. 1.3: Metabolism reactions of MSH [35]. The metabolic processes of MSH 
include defensive reactions against ROS, RNS and xenobiotic agents, shown in red; 
degradation reactions during nutrient starvation, shown in green, and metabolic 
reactions wherein MSH act as a cofactor for the growth of mycobacteria, shown in 
blue. 
 
1.3.2.1  Maintenance of the intracellular reducing environment  
Mycobacteria utilize MSH to reduce both ROS and RNS [5, 14]. Thiol peroxidases 
catalyse the reduction of ROS into MSSM and water. MscR reduce MSNO (MSNO is 
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generated from the reaction of MSH with nitric oxide) to mycothiol-N-
hydroxysulfenamides, which is ultimately transformed into MSSM and nitrate (Figure 
1.3). In addition, MscR assists with the detoxification of formaldehyde. The 
elimination of the reactive species generates large amounts of MSSM; however, the 
ratio of MSH to MSSM is crucial to the mycobacteria to maintain their intracellular 
environment. Mtr, a NADPH-dependent flavoprotein, helps to maintain the 
MSH/MSSM ratio by reducing MSSM to two MSH molecules.  
In 2001, Patel and Blanchard suggested a catalytic mechanism of M. tuberculosis Mtr 
based on pH and kinetic isotope effect studies done with various substrates. This 
mechanism involves three catalytically active sites situated at His444, Cys39 and Cys44 
(Scheme 1.5) [36]. The binding of the oxidized Mtr to NADPH results in the 
 
 
Scheme 1.5: The proposed catalytic mechanism of Mtr. Scheme adapted from Patel 
et al., 2001[36]. 
oxidation of NADPH to NADP+ and the concomitant reduction of Mtr due to the 
transfer of two electrons to the active-site of the enzyme. His444 is thought to stabilize 
the reduced active-site disulfide of the enzyme. In addition, it shares a common 
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electron with Cys39 which reacts with the substrate, MSSM, resulting in the release of 
one molecule of MSH. Release of the first MSH is followed by the release of the 
second MSH which results in the generation of an enzymatic disulfide (oxidized Mtr), 
completing the mechanism of Mtr. The reductive half reaction is the rate-limiting step 
in the redox pathway. 
 
1.3.2.2 Detoxification of electrophilic xenobiotics 
Detoxification of xenobiotics in actinomycetes is facilitated by MSH and Mca (Figure 
13) [37]. This was discovered by Newton et. al. [37] in an attempt to alkyate the free 
thiol of MSH by adding monobromobimane (mBBr) to M. smegmatis cultures. 
Addition of mBBr to the cultures converted MSH into a bimane derivative (MsmB) 
which was subsequently cleaved into GlcN-Ins and the bimane derivate of N-
acetylcysteine (AcCySmB). AcCySmB was excreted from the cell into the medium, 
while GlcN-Ins was recycled in mycothiol biosynthesis. Mca was identified as the 
enzyme responsible for liberation of GlcN-Ins and AcCySmB, and was characterised 
as a zinc-dependent N-acyl hydrolase with about 42% sequence homology with 
MshB [14, 37].  
The catalytic mechanism of Mca involves the binding of MSH to an electrophilic 
xenobiotic via a glucosaminyl-amide bond, resulting in the formation of MS-
conjugates [14, 37]. The conjugate is subsequently hydrolysed at the glucosaminyl-
amide bond by Mca, yielding a mercapturic acid derivate and GlcN-Ins. Finally, the 
mercapturic acid derivative is excreted, while GlcN-Ins is used to reform MSH, 
through the action of MshC and MshD. Mca cleaves a number of mycothiol 
conjugates including MSmB, MS-acetophenone and MS-rifamycin through binding to 
the mycothiol moieties of these compounds. MSmB has been reported to be the best 
substrate for Mca identified to date. In addition Mca is believed to be the major player 
in the development of drug resistance in M. tuberculosis [14]. 
 
1.3.2.3 Mycothiol as a cofactor, cysteine reservoir and/or carbon source  
During nutrient starvation mycobacteria utilise gentisate as an alternative carbon 
source via the gentisate pathway which is catalyse by gentisate 1,2-dioxygenase to 
give maleylpyruvate which is converted into fumarylpyruvate which is eventually 
hydrolysed into pyruvate and fumarate by fumarylpruvate hydrolase (Figure 3). The 
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conversion of maleylpyruvate into fumarylpyruvate is catalysed by maleylpyruvate 
isomerase, which uses MSH as a cofactor [14, 35, 38, 39]. Furthermore, MSH can 
act as a reservoir for Cys and GlcNAc. This is achieved when Mca breaks the MSH 
down into Cys and GlcNAc, to generate pyruvate as a carbon source during the 
Krebs cycle [14].  
 
1.4 The MSH biosynthetic pathway and MSH-dependent enzymes 
as potential targets for the development of new anti-TB drugs 
Gene knockout studies of the MSH biosynthetic pathway enzymes and MSH-
dependent enzymes have shown that MSH is essential for the growth and survival of 
M. tuberculosis [14, 23, 40, 41]. These observations suggest that the MSH 
biosynthetic enzymes and MSH-dependent enzymes could be potential targets for 
development of new anti-TB drugs against the latent and active forms of TB. In this 
regard the MSH-dependent enzyme Mca and the MSH biosynthetic pathway enzyme 
MshB have specifically been highlighted as potential drug targets [23, 42-45]. 
 
1.4.1 Mca and MshB as potential targets 
Mca and MshB play an important role in the biosynthesis pathway and utilization of 
MSH [14, 37]. MshB is responsible for the conversion of GlcNAc-Ins to GlcN-Ins 
during the biosynthesis pathway, while Mca is responsible for the cleavage of the 
amide bond of MSH-S-conjugates to give GlcN-Ins and AcCys-S-conjugates during 
detoxification process of alkylating agents and toxins material in the mycobacteria 
system. The GlcN-Ins produced from both the enzymatic reactions is used by MshC 
and MshD to generate MSH which is then used in several metabolic reactions 
(Figure 1.3) [14, 35]. MshB and Mca have been highlighted as potential drug target 
due to several factors. First, Mca and MshB show a high level of similarity in regards 
to both primary sequence (homology) and mechanism, suggesting that inhibitors 
developed against the one protein would also target the other. This was in fact found 
to be the case in recent studies [23, 43]. There is also very little homology between 
these enzymes and their eukaryotic counterparts, suggesting that specificity of 
inhibition should be achievable. Mca is also one of the earliest MSH-dependent 
enzymes to be discovered and assayed, so that much information about it is know, 
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while the catalytic mechanism and structure of MshB is well known, which is 
essential for rational drug design [24, 27, 28, 44]. Taken together, these factors have 
led to various studies that focused on developing inhibitors against these enzymes. 
  
1.4.2 Previous studies focussing on Mca and MshB inhibitors 
development 
Mca has received most attention as a potential drug target since it is one of the 
earliest MSH-dependent enzymes identified, and based on its uniqueness compared 
to other known eukaryotic enzymes [41]. The first inhibitor compounds against Mca 
were isolated from an Australian non-verongid sponge of Oceanipia species by the 
Bewley group in 2001 [41]. They isolated and studied the structure of five novel 
alkaloids compounds from the marine extract and evaluated their potential as 
inhibitor compounds against Mca using fluorescence-detected HPLC. Out of the five 
novel compounds, four were found to show inhibition activity against Mca. This was 
followed by several other studies wherein derivative compound based on these 
natural products were synthesized and tested as potential inhibitors of Mca [45, 46]. 
However, the development of more potent inhibitors of Mca were stalled by the lack 
of appropriate activity assays and the lack of structural and mechanistic information 
of the enzyme, which is essential for rational drug design. Subsequently, the 
purification and characterization of MshB by Fahey group [47] paved the way for the 
Bewley group to develop the first inhibitor compounds against MshB through 
molecular docking studies of the active site, wherein the inhibitor compounds were 
found to display inhibition activity not only on MshB, but also on Mca [43]. Since the 
publication of these results, subsequent studies have focussed more on the 
development of drugs against MshB due to the knowledge of its catalytic mechanism 
and the availability of its structure [42].  
 
1.4.3 Shortcomings and current needs 
Currently, all drug development studies against MshB are stalled by poor availability 
of it natural substrate (GlcNAc-Ins), and the lack of suitable alternative substrates 
that can be used to assay its activity. Also, the production of inhibitor compounds and 
substrate analogues by synthetic elaboration of the GlcNAc-Ins scaffold yields only 
small quantities of material, and even these are difficult to generate. In addition, there 
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is currently no continuous assay available by which the MshB reaction can be 
assayed, making it difficult to screen and characterize libraries of inhibitor 
compounds that target this enzyme. Therefore, to improve the success of studies that 
target inhibition of MshB (and/or Mca) for the development of new anti-tuberculosis 
drugs, these shortcomings must be addressed. This can be done by devising new 
strategies that will enable the large (gram quantity) scale production of GlcNAc-Ins 
and compounds based on the GlcNAc-Ins scaffold (to increase the availability of the 
reaction substrate). Additionally, the development of a continuous MshB activity will 
greatly facilitate the ability to libraries of inhibitory compounds.  
1.5 Objectives and aims of the project 
This project aimed to address these shortcomings through two main objectives. The 
first objective was to develop a high-throughput continuous assay for MshB that can 
be used to identify new inhibitors of the enzyme by screening existing compound 
libraries. The second objective was to prepare and characterize a biocatalyst that 
can be used for the preparation of new alternative substrates and natural substrate of 
MshB.  
The specific aims of the project can therefore be stated as follows:  
Aim 1: Investigation and characterization of known alternative substrates of MshB for 
use in the development of a new continuous assay of the enzyme.  
A short introduction to the studies that led to the realization of this aim, and the 
description of the obtained results, are provided in Chapter 2.  
Aim 2: Engineering of an α-N-acetylglucosaminidase for biocatalytic preparation of 
thioglycosides as alternative substrate of MshB  
The work done on the generation of such α-thioglycoligase biocatalysts is reported in 
Chapter 3, and is accompanied by a brief introduction to the use of glycosidase 
enzymes as biocatalysts. 
Taken together, the work presented in this thesis represents a significant step 
forward in our attempt to the MSH biosynthetic enzymes and MSH-dependent 
enzymes as potential targets for antituberculosis drug development. 
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Chapter 2: Development of a novel 
high-throughput continuous MshB 
assay  
2.1.  Introduction  
MshB is a metal-containing GlcNAc-Ins N-deacetylase that catalyzes the third step of 
MSH biosynthesis (Figure 2.1, and Section 1.3.1.2), and which has been highlighted 
as a potential target for drug development [1]. However, two practical factors have 
prevented such drug development studies that target MshB from advancing: first, the 
lack of availability of its substrate, GlcNAc-Ins, and second, the lack of a general 
continuous assay method that can be used to determine the enzyme’s activity. This 
is partly because the substrates and reaction products of MshB are 
spectrophotometrically inactive, which makes it difficult to follow the reaction directly. 
This chapter described the results of the studies performed to develop a general 
























Fig. 2.1: The MshB-catalyzed reaction, in which an acetyl group is removed from 
GlcNAc-Ins. 
 
To date two discontinuous MshB assays have been developed, both of which are 
based on the derivatization and subsequent detection of the MshB reaction products. 
These assays either use the fluorescent derivatization agent 6-aminoquinolyl-N-
hydroxysuccinimidyl carbamate (AccQ-FluorTM) [2] or fluorescamine (FSA) [3] (Figure 
2.2), both of which selectively react with free amine groups. The deacetylation of 
GlcNAc-Ins by MshB to form GlcN-Ins exposes a free amine group which allows the 
binding of these fluorescent compounds. 
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Fig. 2.2: The fluorescent derivatization agents, AccQ-Fluor and fluorescamine, used 
to analyse the reaction products of MshB. 
 
2.1.1 Previous MSH-related studies based on the use of AccQ-Fluor 
AccQ-Fluor was first used by Anderberg et al, [2] as a derivatization agent to 
evaluate the potential metabolites in the MSH biosynthesis pathway of 
Mycobacterium smegmatis. They employed AccQ-Fluor to determine the amounts of 
glucosamine (GlcN) and GlcN-Ins in cell extracts. The binding of AccQ-Fluor to the 
amine group of these compounds releases N-hydroxysuccinimide (Figure 2.3), after 
which the reaction mixture is analysed with high-performance liquid chromatography 
(HPLC).  
 
Fig. 2.3: Reaction of AccQ-Fluor  with the free amine of GlcN and GlcN-Ins 
 
The AccQ-FluorTM method was also used by Newton et al. [4] to confirm GlcNAc-Ins 
as a substrate for MshB [4] and for the full characterization of M. tuberculosis MshB 
with GlcNAc-Ins as natural substrate. It was also used to determine the reactivity of 
MshB with various alternative substrates, including N-acetylglucosamine (GlcNAc), a 
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simplified analogue of GlcNAc-Ins in which the inositol portion of the molecule has 
been removed (Figure 2.4) [5]. 
 
Fig. 2.4: The structure of N-acetylglucosamine 
 
2.1.2 Previous MSH-related studies based on the use of fluorescamine 
(FSA) 
The second derivitization agent, FSA, is a spiro compound that only reacts with 
primary amines to form a fluorescent product which is detected at λex = 390 nm and 
λem = 475-490 nm. In 2011 Huang and Hernick [3] used derivatization with FSA to 
develop an MshB assay in which GlcNAc was used as an alternative substrate 
(Figure 2.5). For this assay, they followed the deacetylation of GlcNAc over a period 
of an hour by quenching the reaction at 10 minutes intervals, followed by FSA-
derivatization and comparison of the signal to that of a standard curve prepared 
using GlcN. The obtained data was subsequently used to calculate the enzyme’s 
steady-state parameters.  
 
Fig. 2.5: MshB reaction with GlcNAc as substrate, and analysis of its reaction 
product GlcN by an FSA derivatization-based assay. 
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2.2 Development of a high-throughput continuous assay of MshB 
activity 
Neither of the assays described above allows the characterization of the MshB 
activity in a continuous fashion, which limits the ability to screen for new drugs 
against this enzyme. In addition, discontinuous assays are laborious and make it a 
cumbersome task to determine the kinetic parameters accuratetly. A previous study 
by our group identified three chromogenic GlcNAc derivatives, namely 2,4-
dinitrophenyl 2-acetamido-2-deoxy-1-thio-α-D-glucopyranose (GlcNAc-SDNP), 4-
nitrophenyl 2-acetamido-2-deoxy-1-thio-α-D-glucopyranose (GlcNAc-SPNP) and 
benzyl 2-acetamido-2-deoxy-1-thio-3,4,6-tri-O-acetyl-α-D-glucopyranose (GlcNAc-
SBn) as potential alternative substrate for MshB based on HPLC analysis of the 
reaction mixtures (Figure 2.6) [6]. These compounds differ from the natural MshB 
substrate GlcNAc-Ins in that the inositol portion was replaced by aromatic groups 
with absorbance spectra in the UV/Vis-range of the spectrum; they were prepared 
with the idea that a change in their absorbance spectra would occur upon their 




Fig. 2.6: The structure of the MshB natural substrate GlcNAc-Ins, and the three 
chromogenic GlcNAc derivatives prepared as potential alternative MshB substrates 
 
Unfortunately no significant changes in the absorbance spectra of these compounds 
were detected during deacetylation by MshB. However, the investigation led to the 
discovery of an S→N intramolecular rearrangement that occurred upon deacetylation 
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of one of the compounds, GlcNAc-SDNP. This rearrangement led to the formation of 
a free SH-group that could react with the known thiol-derivatization agent 5,5′-
dithiobis-(2-nitrobenzoic acid) (DTNB, or Ellman’s reagent). In this manner the 
alternative substrate could be exploited for the development of the first continuous 
assay of MshB.  
To achieve Aim 1 of this study as described in the previous chapter, GlcNAc-SDNP 
was characterized as an alternative substrate of MshB using FSA-and DTNB-based 
activity analyses. Subsequently, a novel, continuous DTNB-based MshB assay was 
developed based on the S→N intramolecular rearrangement of GlcN-SDNP. The full 
description of this work, and the results that were achieved was published in May 
2012 in Organic & Biomolecular Chemistry (OBC) [7].  
As the second co-author of this publication I was responsible for obtaining the data 
and results presented in Figure 3A (absorbance spectra), Table 1 (FSA-and DTNB-
based activity data) and Figure 5 (activity profiles of GlcNAc-SDNP with MshB using 
continuous and end-point analysis by means of DTNB derivitazation) of the 
publication. I also assisted in conducting the experiments done to confirm the S→N 
intramolecular rearrangement of GlcN-SDNP (MS results presented in Figure 4). The 
first author, Dr D.A. Lamprecht, was responsible for the chemical synthesis of the 
chromogenic compounds, as well as the characterization of these compounds as 
alternative substrate for MshB by means of HPLC analysis (Figure 3B and data in 
Table 1). Dr. Lamprecht also conducted the experiments done to confirm the S→N 
intramolecular rearrangement of GlcN-SDNP (LC-ESI-MS data presented in Figure 
4), although this was done with my assistance. 
This study was done in collaboration with the research group of Dr A. Jardine (UCT) 
and with the assistance Dr H. Eastwood and Prof. K.J. Naidoo who performed the 
computational and MshB docking studies (Figure 2). The study was done under the 
supervision and guidance of Prof. E. Strauss (Dept. of Biochemistry, SU) and Dr. A. 
Jardine (Dept. of Chemistry, UCT). 
The full published version of the OBC publication is reproduced on the following 
pages of this thesis1. The supplementary information that accompanied the article 
is provided as Addendum A. 
                                                            
1 [DOI: 10.1039/C2OB25429h] – Reproduced by permission of The Royal Society of 
Chemistry. http://pubs.rsc.org/en/content/articlelanding/2012/ob/c2ob25429h  
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An enzyme-initiated Smiles rearrangement enables the development of an
assay of MshB, the GlcNAc-Ins deacetylase of mycothiol biosynthesis†
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MshB is the N-acetyl-1-D-myo-inosityl-2-amino-2-deoxy-D-glucopyranoside (GlcNAc-Ins) deacetylase
active as one of the enzymes involved in the biosynthesis of mycothiol (MSH), a protective low
molecular weight thiol present only in Mycobacterium tuberculosis and other actinomycetes. In this study,
structural analogues of GlcNAc-Ins in which the inosityl moiety is replaced by a chromophore were
synthesized and evaluated as alternate substrates of MshB, with the goal of identifying a compound that
would be useful in high-throughput assays of the enzyme. In an unexpected and surprising finding one of
the GlcNAc-Ins analogues is shown to undergo a Smiles rearrangement upon MshB-mediated
deacetylation, uncovering a free thiol group. We demonstrate that this chemistry can be exploited for the
development of the first continuous assay of MshB activity based on the detection of thiol formation by
DTNB (Ellman’s reagent); such an assay should be ideally suited for the identification of MshB inhibitors
by means of high-throughput screens in microplates.
Introduction
The ability to counteract the effects and consequences of oxi-
dative stress is an important adaptation that ensured the survival
of organisms in an aerobic environment.1 Moreover, many
pathogenic microorganisms also maintain virulence by resisting
the oxidative killing mechanisms of the human immune system’s
defences. Low molecular weight (LMW) thiols play a key role
in these processes by acting as redox buffers, thereby helping to
maintain redox homeostasis within cells.2 In most organisms—
including humans—the principle LMW thiol is glutathione.
However, many Gram-positive bacteria do not contain gluta-
thione, and evidence suggests that they instead rely on the meta-
bolic cofactor coenzyme A (CoA) and/or the recently discovered
bacillithiol (BSH) as redox buffer.3 The actinomycetes, which
include Mycobacterium tuberculosis (Mtb), the causative agent
of tuberculosis, produce mycothiol (MSH) as their principal
LMW thiol.4,5 These differences, and the essential requirement
for MSH under various stress conditions, led to the identification
of the biosynthesis and utilization of this novel thiol as a poten-
tial target for tuberculosis drug development.6
MSH is biosynthesised from UDP-GlcNAc, L-myo-inositol-1-
phosphate (L-Ins-1-P), L-cysteine and acetyl-CoA through the
sequential action of four enzymes, designated MshA, MshB,
MshC and MshD (Scheme 1).4,7 A fifth enzyme, an as yet un-
identified phosphatase tentatively named MshA2, has also been
implicated in the reaction.8 Two other enzymes also play impor-
tant roles in the maintenance of MSH levels: the NADPH-depen-
dent oxidoreductase mycothiol disulfide reductase (Mtr) is
responsible for the reduction of mycothiol disulfide (MSSM)
formed through the oxidation of MSH,9,10 while the mycothiol-
S-conjugate amidase (Mca) cleaves the cysteine amide of
mycothiol-S-conjugates formed in the MSH-dependent detoxifi-
cation of alkylating agents, free radicals and xenobiotics. In the
process it forms 1-D-myo-inosityl-2-amino-2-deoxy-D-glucopyra-
noside (GlcN-Ins) and a mercapturic acid derivative, which is
excreted.11
The mycothiol biosynthetic enzyme MshB is one of the
enzymes in the pathway that has been identified as an attractive
potential target for drug discovery. This was based on the fact
that MSH levels in knockout mutants of the mycobacterium
M. smegmatis that lacked the mshB gene were reduced up to
95% compared to wild-type (the low residual formation of MSH
was ascribed to the promiscuous nature of Mca).12 MshB is a
metal-dependent hydrolase13 that catalyses the deacetylation of
N-acetyl-1-D-myo-inosityl-2-amino-2-deoxy-D-glucopyranoside
(GlcNAc-Ins, 1) to form the amino sugar GlcN-Ins. Structural
†Electronic supplementary information (ESI) available: Full chromato-
grams and associated mass spectra from the LC-HR-ESI-MS ana-
lyses, and NMR spectra of the thioglycosides 3a–c. See DOI:
10.1039/c2ob25429h
aDepartment of Biochemistry, Stellenbosch University, Private Bag X1,
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analysis showed that the active site metal—previously thought to
be zinc, although recent studies have found higher activity with
iron14—is coordinated to two histidine residues (His13 and
His147) and an aspartate (Asp16).15,16 The metal is also bound
to the acetamidocarbonyl oxygen of the substrate and a water
molecule, which was proposed to be activated for nucleophilic
attack through this interaction. This has been confirmed in recent
mechanistic studies, which also showed that MshB uses a
general acid–base mechanism in which Asp15 and His144 act as
the general base and acid catalysts respectively, while Tyr142
plays a dynamic role that includes stabilization of the oxyanion
intermediate (Scheme 2).17
The study of MshB activity and inhibition poses two major
practical challenges. First, its natural substrate can only be
obtained by means of lengthy multi-step synthetic pro-
cedures,18,19 or by isolation of mycothiol-S-conjugates from
natural sources, followed by treatment with Mca to release
GlcN-Ins (Scheme 1).20 Consequently, many recent MshB
studies made use of commercially available GlcNAc (2) as an
alternate minimal substrate instead,14,17,21 even though it has
been shown that MshB is ∼100-fold less active towards this
compound.4,20 Additionally, other groups have invested
significant synthetic effort in the discovery of alternate MshB
substrates that give reasonable levels of activity.22 Second, the
general method for the assay of MshB activity involves derivati-
zation of reaction products followed by lengthy HPLC
analysis, which precludes high-throughput screening.22–24 A
significant advancement has been the recent development of
a fluorescence-based microplate assay that measures MshB
activity based on the reaction of fluorescamine (FSA) with the
free amine of the deacetylation product after the reaction has
been quenched.21 However, its mechanism precludes its use for
the screening of compound libraries for potential MshB inhibi-
tors in which similarly reactive functional groups are
represented.
In this study we sought to address these shortcomings by the
incorporation of chromogenic functional groups into the struc-
tures of potential alternate MshB substrates. Our strategy was to
exploit any changes that occur in the absorbance spectra of such
compounds upon deacetylation for use in a continuous spectro-
photometric assay. In the process we uncovered an unexpected
enzyme-initiated Smiles rearrangement of one of the substrates,
which allowed the development of a new, sensitive microplate-
based assay of MshB activity.
Scheme 1 Biosynthesis and recycling of mycothiol (MSH).
Scheme 2 Proposed catalytic mechanism of MshB, highlighting the active site residues involved in catalysis.17
This journal is © The Royal Society of Chemistry 2012 Org. Biomol. Chem., 2012, 10, 5278–5288 | 5279
Stellenbosch University  http://scholar.sun.ac.za
Results and discussion
Rationale and strategy
Previous studies of MshB and Mca have shown that modification
of the inosityl moiety of GlcNAc-Ins is usually tolerated by
these enzymes, although often to the detriment of the observed
activity.19,22 We therefore chose to investigate whether the re-
placement of the inosityl group by aromatic moieties would
similarly result in compounds accepted as substrates by MshB.
More specifically, we set out to use aromatic groups that are
known strong chromophores, anticipating that deacetylation of
such alternate substrates may result in changes in their absor-
bance maxima. Such changes would allow the continuous spec-
trophotometric assaying of MshB activity, which would be ideal
for high-throughput screening. We decided to introduce such
groups via S-glycoside linkages, since the syntheses of several
α-GlcNAc thioconjugates have been reported.19,22,24–26
Three aromatic groups were chosen as replacements of the
inosityl group of GlcNAc-Ins for this study (Fig. 1). In the first
case a para-nitrophenyl group, a well-known chromophore uti-
lized in several different enzymatic assays, was selected to give
GlcNAc-SPNP (3a). Second, a 2,4-dinitrophenyl group was
chosen to give GlcNAc-SDNP (3b) as a potential alternate sub-
strate. The extra nitro-group was expected to increase the absor-
bance intensity of the chromophore, thereby potentially also
increasing its sensitivity to any changes that might occur in its
absorbance spectrum upon deacetylation. Third, a simple benzyl
group was selected as a reference for the study of the other two
groups, as its absorbance was unlikely to be affected by deacety-
lation due to its distant location from the acetamido group. More-
over, a recent study found that GlcNAc-SPh (the phenyl
thioglycoside) showed ∼30% of the activity of the native
GlcNAc-Ins substrate, suggesting that GlcNAc-SBn (3c) might
similarly act as a good alternate substrate, thereby also acting as
a positive control.22
Docking studies and computational chemistry
One of the alternate substrates that we proposed to use in this
study, the dinitrophenyl derivative 3b, was recently reported to
be inactive in a MshB assay that depended on the fluorescent
derivatization of the free amine of the expected product, fol-
lowed by HPLC analysis.22 While this result indicated that 3b
would not be suitable for the purposes of this study, it seemed
curious in light of the good activity observed for the structurally
analogous GlcNAc-SPh using the same assay. Evaluation of the
available structures of recombinant MshB indicated that its
binding pocket is cavernous and that it should be able to accom-
modate a variety of substrates, as indicated by the green enclo-
sure shown in Fig. 2.15,16 However, charged or polar amino
acids predominate in the binding cavity, with few well-defined
hydrophobic regions. This suggested that the hydrophobic aro-
matic groups of the alternate substrates would not be accommo-
dated in the MshB active site, although this could be offset by
the potential of the nitro substituents to act as hydrogen bond
acceptors. To establish whether 3a and/or 3b would be excluded
from MshB’s active site based on such structural considerations,
we set out to perform docking and molecular dynamics studies
using one of the available MshB structures (PDB: 1Q74).16
While the active site zinc ion is clearly visible in this structure, it
does not contain any other bound ligands. The natural substrate
GlcNAc-Ins (1) and minimal substrate GlcNAc (2) were there-
fore also included in the analysis for comparative purposes.
The results of the molecular dynamics studies performed with
the solution-equilibrated MshB structure indicated that the
docked MshB–ligand complexes with good scores have the acet-
amidocarbonyl oxygen in close proximity to the zinc, which is
consistent with the current mechanistic understanding of metal-
dependent deacetylases.13 Moreover, the relatively large active
site cavity volume permits two favourable docked-ligand geome-
tries for each of the ligands, both of which have the acetamido-
carbonyl oxygen placed in a manner allowing catalysis to take
place. For the natural substrate GlcNAc-Ins, the two binding
Fig. 1 Structures of alternate MshB substrates used in this study.
Fig. 2 Molecular docking analysis of the MshB active site binding
pocket (enclosure shown in green) identifies two possible binding orien-
tations for the native substrate GlcNAc-Ins (1), shown in red (geometry
1) and blue (geometry 2) respectively. His13 which coordinates zinc,
and the general acid catalyst His144 are shown, as well as the hydro-
phobic residues at the base of the pocket.
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pocket orientations can be defined using its coordination to the
zinc ion as pivot, and its displacement relative to His13 and
Asp16 as reference points (Fig. 2). In geometry 1, GlcNAc-Ins
extends into a pocket facing down and away from His13, while
in geometry 2 GlcNAc-Ins stretches across into a binding pocket
that is orthogonal to geometry 1. The results indicate that for
GlcNAc-Ins there may be a small but significant energetic pre-
ference for geometry 1 over geometry 2.
In regards to the alternate substrates, the docking analysis indi-
cates that the minimal substrate GlcNAc (2) prefers binding in
geometry 2, which may partially explain its reduced activity.
Similarly GlcNAc-SPNP (3a) also prefers binding in geometry
2, while GlcNAc-SDNP (3b) prefers geometry 1. The analysis
also shows that regardless of the binding geometry, the aromatic
rings of both proposed alternate substrates can be accommodated
in the same pocket that binds inositol. However, the presence of
the hydrophobic residues Val10, Phe9 and Val134 at the base of
the pocket that surrounds geometry 1 would seem to indicate
that this would be the binding mode most likely to compensate
for the loss of the various hydrogen bonding interactions when
the inosityl moiety of GlcNAc-Ins in replaced by an aromatic
group.
Taken together, the results of the docking studies suggest that
3a and 3b would most likely act as alternate substrates for
MshB, with activities similar to that previously observed for
GlcNAc-SPh.22
Synthesis of potential chromogenic substrates of MshB
The α-GlcNAc-mercaptan (4) has previously been used in the
synthesis of a range of α-thioglycosides—including analogues
of MSH—by simple nucleophilic substitution using an appropri-
ate electrophile.19,26 We therefore decided to expand on this
established chemistry for the synthesis of the α-thioglycosides
3a–c (Scheme 3). Triethylamine-mediated S-alkylation of 4 with
aryl fluorides or benzyl bromide gave the desired O-acetylated
thioglycosides (5a–c). Subsequent O-deacetylation gave the
unprotected thioglycosides (3a–c). As expected, the coupling
constants of the anomeric protons were all consistent with that of
α-coupled thioglycosides.
Confirming MshB activity with alternate substrates by HPLC
With the thioglycosides 3a–c in hand we set out to demonstrate
that these are indeed accepted by MshB as alternate substrates.
The UV-visible spectra of 3a–c showed that, as predicted, the
nitrophenyl-containing 3a and 3b have large extinction
coefficients at ∼325 nm and ∼320 nm respectively, while the
benzyl-containing 3c has a relatively poor absorbance with a
maximum at ∼254 nm (Fig. 3A). Nonetheless, the presence of
the chromophoric groups in all three cases allowed their direct
analysis by HPLC, which provided for a simple method whereby
their potential deacetylation by MshB could be monitored. Sub-
sequent incubation of MshB individually with 100 μM each of
3a–c showed a time-dependent decrease for all three compounds,
confirming that they indeed act as alternate substrates of the
enzyme (Fig. 3B). Integration of the peak area at each time point
allowed for the HPLC results to be converted to time-course data
by comparison to a standard curve prepared independently. In
this manner the specific activity of the enzyme towards each sub-
strate could be calculated (Table 1). These values indicated that
MshB has a similar specific activity for all three the alternate
substrates, which is ∼12% of the value previously determined
for the natural substrate GlcNAc-Ins using HPLC analysis of the
fluorescent derivative of the product.27 However, it is about an
order of magnitude better than the value determined for the
minimal substrate GlcNAc in the same manner, indicating that
Scheme 3 Synthesis of thioglycosides 3a–c. (i) 1-fluoro-4-nitroben-
zene (for a), 1-fluoro-2,4-dinitrobenzene (for b) or benzyl bromide (for
c), Et3N, CH2Cl2, 25 °C. (ii) MeOH, H2O, acetone, Amberlite IRA-400
(OH−). The R-groups are defined in Fig. 1.
Fig. 3 Characterization of 3a–c as potential alternate MshB substrates.
Panel A, UV-vis spectra of 3a–c at 200 μM. Panel B, HPLC analysis of
100 μM each of 3a, 3b (at 320 nm) and 3c (at 254 nm) incubated in the
presence of MshB followed by heat inactivation at set time intervals,
shows a time-dependent decrease in the concentration of each
compound.
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the thioglycosides 3a–c may act as suitable alternative substrates
for the assay of MshB activity.
Confirmation of the formation of the expected products upon
deacetylation of 3a–c by MshB
Since synthetic standards of the expected deacetylation products
of 3a–c were not available, the HPLC-based MshB activity
assay described above could only be used to confirm the dis-
appearance of substrate and not the formation of these products.
To confirm that MshB treatment of 3a–c yields products contain-
ing free amino groups, we employed the recently reported MshB
assay in which its substrate (GlcNAc in the original description)
is incubated in the presence of the reactive fluorophore FSA.21
The FSA reacts with the free amine of the deacetylated product
as it is formed to give a fluorescent conjugate, thereby providing
for the monitoring of product formation—and consequently
MshB activity—by fluorimetry.
The activity of MshB towards GlcNAc and the thioglycosides
3a–c (5 mM in 10% DMSO) were monitored in this manner
over a period of 1 h. The observed increase in fluorescence for
each substrate over time was subsequently converted to a change
in concentration over time using a standard curve prepared from
known concentrations of glucosamine (GlcN); in doing so, the
assumption was made that the reactivity of the deacetylated pro-
ducts of 3a–c towards fluorescamine would be similar to GlcN,
and that the rates obtained in this manner (after adjustment for
any background using a control sample containing no substrate)
would allow for a direct comparison of the activity of MshB
towards the respective substrates.
Surprisingly, the resulting data (Table 1) gave rise to a very
different activity profile than the one determined by HPLC
analysis. The FSA-based assay highlights GlcNAc-SBn 3c as
being the preferred MshB substrate among the thioglycoside,
showing a specific activity ∼6-fold that of GlcNAc 2, while
GlcNAc-SPNP 3a and GlcNAc-SDNP 3b show no or very low
activities (with large errors). Since the HPLC-based assay clearly
indicated the disappearance of all three thioglycosides, this
finding suggested that the products formed upon deacetylation of
3a and 3b do not contain free amine groups that are available for
reaction with FSA. We next set out to establish a possible
mechanistic basis for such an outcome.
Deacetylation of GlcNAc-SDNP unmasks a free thiol:
an enzyme-initiated Smiles rearrangement
We considered that the unmasking of the free amino group of 3a
and 3b could lead to a possible intramolecular rearrangement
that results in this group being blocked again, thereby preventing
their reaction with FSA. Such a case was reported by Kondo
et al., which found that S-(2,4-dinitrophenyl)cysteine undergoes
a facile base-catalyzed S → N rearrangement to form N-(2,4-
dinitrophenyl) cysteine.28 This type of rearrangement, which
falls under a broad category of intramolecular aromatic nucleo-
philic substitution reactions, involves the formation of an anionic
σ complex intermediate, also referred to as a Meisenheimer
complex. Such rearrangements were first reported by Smiles in
1930, and are therefore known by his name.29 In the experiment
by Kondo et al., the reaction was performed by incubating
S-(2,4-dinitrophenyl)cysteine with different organic bases,
including imidazole. This suggested that enzyme-borne bases
could also promote such Smiles rearrangements, and that this
could be the basis for the surprise finding that 3a and 3b are see-
mingly inactive in the FSA-based MshB assay.
A Smiles rearrangement of the thioglycoside substrates after
deacetylation by MshB should unmask a free thiol group, as
shown for 3b in Scheme 4. Since the concentration of free thiols
can be established through reaction with 5,5′-dithiobis-(2-nitro-
benzoic acid) (DTNB, or Ellman’s reagent), GlcNAc (acting as
negative control) and 3a–c was individually incubated with
MshB. The reactions were stopped at set time intervals, followed
by treatment with DTNB and measurement of the increase in
absorption at 412 nm to determine the rate of formation of
2-nitro-5-thiobenzoate (NTB, 8), if any.
The results (Table 1) showed an increase only in the case of
GlcNAc-SDNP 3b, with none of the other substrates showing an
increase above the background rate (no substrate control). More-
over, the rate observed for 3b in this assay is very similar to the
rate seen for 3c in the FSA-based assay. This finding confirms
that GlcNAc-SDNP 3b does act as an alternate substrate for
MshB, and that its apparent inactivity (based on the results of
the FSA-based assay and as reported in a previous study that
used AccQ-Fluor derivatization followed by HPLC analysis) is
due to an S → N Smiles rearrangement.
The observation that GlcNAc-SPNP 3a does not show a
similar unmasking of its thiol, while also being unreactive in the












GlcNAc-Ins (1) 220 ± 4027 7.21 ± 1.3127
GlcNAc (2) 3 ± 227 0.10 ± 0.0727
HPLC (direct)d GlcNAc-SPNP (3a) 26.9 ± 1.3 0.88 ± 0.04
GlcNAc-SDNP (3b) 28.4 ± 3.0 0.93 ± 0.10
GlcNAc-SBn (3c) 25.4 ± 3.0 0.83 ± 0.10
Fluorescamine
(FSA)e
GlcNAc (2) 19.1 ± 3.4 0.63 ± 0.11
GlcNAc-SPNP (3a) ∼0 ∼0
GlcNAc-SDNP (3b) 4.2 ± 3.7f 0.14 ± 0.12
GlcNAc-SBn (3c) 122.2 ± 17.0f 4.01 ± 0.56
DTNBe GlcNAc (2) ∼0 ∼0
GlcNAc-SPNP (3a) ∼0 ∼0
GlcNAc-SDNP (3b) 145.8 ± 15.9 4.78 ± 0.52
GlcNAc-SBn (3c) ∼0 ∼0
aActivity values determined in this study represent the average of three
independent measurements, with the standard error shown. bCalculated
from the specific activity data. cUsing 100 μM substrate in water, and
0.5 μM MshB. dUsing 100 μM substrate in water, and 2 μM MshB.
eUsing 5 mM substrate in 5–10% DMSO, and 1 μM MshB. fBased on a
standard curve prepared with GlcN.
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FSA assay, may be due to the reversible formation of the corres-
ponding Meisenheimer complex that is less stabilized by the
single nitro group, and which therefore does not complete the
rearrangement. Since the docking studies indicated that 3a and
3b may prefer to take on different binding modes, this might
also play a role in differentiating their activity profiles. However,
no direct evidence in support of either analysis can be provided
at this stage.
Identification of the Smiles rearrangement product
We subsequently set out to positively identify and study the
Smiles rearrangement product by its chemical synthesis;
however, all attempts in this regard failed, as all the conditions
used for N- and/or O-deacetylation led to the formation of
N-(2,4-dinitrophenyl) glucosamine and H2S. We therefore
attempted its identification by LC-HR-ESI-MS analysis instead.
Comparison of reaction mixtures that contained 3b in either the
absence or presence of MshB indicated the enzyme-mediated
formation of the deacetylation product 6 but not its rearrange-
ment product 7 (Fig. 4). This identification is based on the analy-
sis of the associated mass spectrum, which showed the formation
of fragments that is in agreement with the structure of 6 but not
7, although it is also possible that a stabilized Meisenheimer
complex would give the same observed fragmentation pattern
(see ESI†); note that all three structures (6, 7, and the complex)
have the same molecular mass. Addition of the reductant tris-
(2-carboxyethyl)phosphine (TCEP) to the reaction mixtures gave
the same result. To establish whether the rearrangement product
is formed, but decomposes prior to or during analysis, DTNB
was added to mixtures after they had been quenched and the pre-
cipitated protein removed. Samples that had been treated in this
manner, and that did not contain TCEP, showed the formation of
a new peak that was identified as the mixed disulfide 9 (Fig. 4);
in the presence of TCEP this peak was not observed.
The results of the LC-HR-ESI-MS analyses confirm the deace-
tylation of GlcNAc-SDNP 3b by MshB to form the deacetyla-
tion product 6, as well as its subsequent rearrangement to form
7. Since the FSA-based assay failed to trap any free amine-con-
taining products, it is most likely that the observation of 6 in
these analyses is due to its formation from the stabilized Meisen-
heimer complex under the acidic conditions used for the MS
analysis; the Meisenheimer complex could also give the same
fragmentation pattern directly (Fig. 4B). Formation of the labile
rearranged product 7 is confirmed by its trapping by DTNB to
Fig. 4 LC-HR-ESI-MS analyses of the product(s) formed in the
MshB-mediated reaction of GlcNAc-SDNP 3b. Panel A, base peak ion
(BPI) chromatogram of a control reaction mixture containing only the
substrate 3b in the presence of the reductant TCEP. Panel B, BPI chro-
matogram of a reaction mixture containing 3b, MshB and TCEP. Panel
C, BPI chromatogram of a reaction mixture containing 3b and MshB
(but no TCEP) that had been treated with DTNB prior to analysis. All
peaks were identified by analysis of the associated mass spectra (the
required and found mass for the major ion in each spectrum is shown)
and observed fragmentation patterns. The full chromatograms and the
associated mass spectra are provided as ESI.†
Scheme 4 Proposed Smiles rearrangement of the MshB-catalysed de-
acetylation product (6) of GlcNAc-SDNP 3b. The formation of the
rearrangement product 7 can be followed by derivatisation with DTNB
(Ellman’s reagent) to form the strong chromophore, 2-nitro-5-thiobenzo-
ate (NTB, 8) and the mixed disulfide 9.
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form the stable disulfide adduct 9; however, in the absence of a
trapping reagent 7 is not observed, in agreement with the diffi-
culties encountered with its chemical synthesis.
Exploiting the Smiles rearrangement to develop a new MshB
assay amenable to high-throughput screening
The confirmed deacetylation of GlcNAc-SDNP 3b by MshB led
us to consider whether this substrate could be used for the devel-
opment of a new assay for MshB activity, which is also amen-
able to high-throughput screening. Towards this end, we first
determined whether product formation could be measured based
on changes that occur in the absorbance spectrum of 3b upon its
deacetylation (and/or subsequent Smiles rearrangement).
However, incubation of 3b in the presence of MshB showed no
significant time-dependent changes in its absorbance at 320 nm
(its absorbance maximum, see Fig. 3A), making direct spectro-
photometric-based activity analysis impossible and necessitating
an alternative strategy.
The reaction of DTNB with free thiols have been used to
assay the activity of several enzymes (including the mycothiol
disulfide reductase, Mtr9) in continuous fashion. Having
confirmed the reaction of DTNB with 7 and the formation of the
mixed disulfide 9 and the associated NTB (8) by-product, we
therefore set out to determine if MshB activity could also be
determined in this manner. Increasing concentrations of 3b
(between 0 and 5 mM) were incubated in the presence of MshB
and DTNB, and the increase in absorbance at 412 nm monitored
in a time-dependent fashion. For comparison, identical reaction
mixtures were incubated without DTNB, stopped at regular time
intervals, and the amount of product formed determined by
DTNB treatment after the enzyme was precipitated and removed
as before.
The progress curves obtained from the continuous monitoring
of MshB activity through NTB release showed an initial lag
period (presumably due to the slow collapse of the Meisenhei-
mer complex) before giving way to the linear increase in NTB
formation. Importantly, a control reaction that contained 100 μM
substrate but no enzyme showed no increase, confirming that the
observed increase in absorbance was due to enzyme activity.
Regression analysis of the linear portions of the progress curves
allowed for the corresponding activity rates to be calculated,
while the rates from the discontinuous assay were determined
from regression analysis of the data obtained at the set time-
intervals at each concentration. The results (Fig. 5) show that the
data obtained by either method give comparable rates at substrate
concentrations of 1 and 5 mM. However, the continuous moni-
toring of activity is clearly superior since it gave data points with
smaller errors, leading to an excellent linear correlation between
activity and substrate concentration over the whole concentration
range measured. In fact, when the activity of reaction mixtures
with less than 1 mM substrate was determined in a discontinuous
fashion, the variation in the replicates became so large that accu-
rate measurements became impossible (data not shown). The
activity obtained using 5 mM 3b (3.4 ± 0.1 min−1 from the con-
tinuous assay, and 5.0 ± 1.0 min−1 for the discontinuous assay)
also correlate well with those obtained for 5 mM GlcNAc–SBn
3c obtained in the FSA-based assay (Table 1). This suggests that
under the assay conditions used, the kinetics of the Smiles
rearrangement do not adversely affect the measurement of
MshB’s deacetylation of 3b by DTNB derivatization.
The finding that MshB’s activity towards 3b as a substrate cor-
relates linearly over the concentration range used (0–5 mM) was
not surprising considering that the KM value determined for
GlcNAc using the FSA assay is 38 ± 4 mM (kcat 46 ±
2.2 min−1).21 However, the poor solubility of 3b in aqueous sol-
utions prevented us from using higher concentrations, and there-
fore the kinetic parameters could not be determined for this
substrate. Nonetheless, the rate obtained for 5 mM GlcNAc-
SDNP using the DTNB-based assay is ∼7–12% of the kcat(Glc-
NAc) obtained in the FSA-(46 ± 2.2 min−1)21 and HPLC-based
(29.4 ± 2.4 min−1)27 assays respectively, suggesting that the
kinetic parameters for 3b do not differ significantly from those
for GlcNAc.
Finally, the result demonstrates that GlcNAc-SDNP 3b acts as
a suitable alternative substrate for MshB, allowing its activity to
be measured continuously using a DTNB-based assay at concen-
trations as low as 50 μM.
Conclusions
In this study we set out to develop a new continuous assay of
MshB activity based on the use of chromogenic substrates. In
the process, we uncovered an unexpected and previously unseen
enzyme-initiated Smiles rearrangement of one of the substrates.
Fig. 5 Activity profile of MshB with GlcNAc-SDNP 3b as substrate,
measured based on the release of NTB (8) after reaction of DTNB
(Ellman’s reagent) with the rearranged deacetylation product 7 (see
Scheme 4). Closed circles (●) represent data points determined through
the continuous monitoring of product formation by performing the reac-
tion in the presence of DTNB; Open circles (○) are data points obtained
by quenching reaction mixtures are regular intervals, followed by DTNB
treatment. All data points represent the average of two separate measure-
ments, with the errors bars indicating the standard deviation. Linear
regression analysis of the (●) data set gives a line with the equation y =
0.6763x + 0.000138. The y-axis labels on the left and right are associ-
ated with the data points to the left and right of the x-axis break respect-
ively; the units are identical in both cases.
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This discovery allowed for the first continuous and sensitive
assay of MshB activity to be developed.
The study of the mechanistic detail of the Smiles rearrange-
ment of deacetylated 3b would be interesting considering not
only the novelty of the enzyme-based initiation of the reaction,
but would also help relate the rate of deacetylation to the kinetic
and thermodynamic factors that control the formation and sub-
sequent collapse of the associated Meisenheimer complex. More-
over, it is also unclear whether the Smiles rearrangement takes
place in the MshB active site, where interaction between the
unmasked thiol and the catalytic metal ion may result in inhi-
bition, or only after the deacetylated product is released.
However, it is quite likely that the rearrangement takes place
upon collapse of the tetrahedral intermediate, and that adjacent
acidic residues such as His144 plays a role in stabilizing the
Meisenheimer complex intermediate. Conversely, the very rigid
platform provided by the glucosamine skeleton, and the presence
of stabilising electron-withdrawing nitro substituents in 3b,
would promote the rearrangement independent of enzyme invol-
vement. A full understanding of the interplay between such con-
siderations would be helpful in further establishing the utility of
the assay.
In conclusion, the serendipitous discovery of GlcNAc-SDNP
3b as an alternate MshB substrate with unique characteristics
provides the opportunity for microplate-based inhibitor screening
of this enzyme, or any other deacetylase reactivity that may
potentiate the Smiles rearrangement by similarly invoking het-
eroatom nucleophiles. This finding may significantly advance
our search of inhibitors of mycothiol biosynthesis as potential
antituberculosis agents.
Materials and methods
General reagents and methods
Chemicals were purchased from Sigma-Aldrich. All reactions
were performed at room temperature unless specified otherwise.
Flash chromatography was performed using a 20 : 1 weight ratio
of silica to crude reaction mixture. Thin layer chromatography
(TLC) was performed on Merck Aluminium Silica gel 60 F254
plates. All compounds containing free amines were visualized on
TLC plates by spraying the plates with ninhydrin solution (1.5%
ninhydrin in n-butanol with 3% AcOH) followed by heating the
plates until the colour developed. All chromogenic compounds
were visualized on the TLC plate under UV light. HPLC ana-
lyses were performed on an Agilent 1100 system with an in-line
DAD detector. LC-HR-ESI-MS analyses were performed using a
Waters Aquity UPLC attached to a Waters Synapt G2 QTOF
mass spectrometer. High resolution ESI-MS analyses were per-
formed on a QTOF Ultima API quadrupole mass spectrometer.
1H and 13C NMR was performed on Varian Unity Inova
600 MHz NMR and Varian VXR 300 MHz NMR spectrometers.
Enzyme assays (fluorometric and spectrophotometric analyses)
were conducted using a Varioskan multimode reader (Thermo
Scientific). An extinction coefficient (ε) of 13 600 dm−3 mol−1 cm−1
was used for the absorbance of 2-nitro-5-thiobenzoate (NTB, 8)
at 412 nm.
Computational methods
Prior to performing the docking calculations the MshB crystal
structure (PDB ID: 1Q74) was protonated using the Karlsberg
pKa prediction tool.
30 The protein was hydrated for molecular
dynamics (MD) simulations using a sphere of 30.0 Å in a
manner similar to one reported previously.31
MD simulations were performed using the CHARMM32b32
program with the CHARMM27 all atom force field for the
protein33 and CSFF for the carbohydrate and inositol.34 In all
MD simulations a water sphere of 30.0 Å containing 11 322
TIP3P35 water molecules as implemented in CHARMM36 were
used. The system was centred about the glycosidic linkage of the
ligand for the simulations. The water molecules that overlapped
with any of the ligand heavy atoms were removed and a spheri-
cal boundary force was applied to the surface of the water sphere
to maintain a consistent water density of 1.0 g cm−1. A constant
temperature of 298.15 K was maintained throughout the simu-
lations using the Nosé–Hover thermostat.37 A buffer region of
2 Å thickness and a dynamic region with 21 Å radius was used
with Langevin dynamics in all simulations. All hydrogen bond
lengths were kept fixed with the SHAKE algorithm and an inte-
gration step of 1 fs was used.
The crystal structure was subjected to 7 ns explicitly solvated
molecular dynamics and then stripped of water molecules, after
which several ligands were docked in the MD solution equili-
brated MshB structure using Glide.38 A cubic volume of side
9 Å, centred on the central zinc atom was selected. A search was
conducted via a grid generation with no constraints in conjunc-
tion with a Van der Waals scaling factor of 1 and a partial charge
cut-off of 0.25. Conformational searches on each ligand were
performed using the Extra Precision (XP) algorithm, where a
maximum of 2000 conjugate gradient steps, a distance dielectric
cut-off of 2 Å and flexible docking were applied on 1200 poses
for every ligand.
Of the conformations generated, those where the Coulomb
and van der Waals interactions summed to values greater than 0
were rejected. To ensure that the ligands generated were confor-
mationally distinct an RMS deviation of 0.5 Å was used. The
100 highest scoring geometries for each molecule were examined
to identify structures where the carbonyl carbon is in close proxi-
mity to the zinc.
Synthesis of α-thioglycoside compounds
4-Nitrophenyl 2-acetamido-2-deoxy-1-thio-3,4,6-tri-O-acetyl-
α-D-glucopyranose (5a). To a solution of compound 426
(280 mg, 0.773 mmol) in 5 ml dichloromethane stirred under a
N2 atmosphere was added 1-fluoro-4-nitrobenzene (164 μl,
2.8 mmol) and triethylamine (130 μl, 1.15 mmol). The reaction
was allowed to stir for 24 h, and then concentrated. The product
was purified from the crude reaction mixture using flash chrom-
atography (2% MeOH/CH2Cl2), resulting in 360 mg (96% yield)
of pure 5a as a yellow amorphous solid. δH (600 MHz, CDCl3,
Me4Si): 1.974 (s, 3H), 2.026 (s, 3H), 2.061 (s, 3H), 2.081 (s,
3H), 4.070 (dd, 1H), 4.254 (dd, 1H), 4.373 (m, 1H), 4.590 (m,
1H), 5.169 (m, 2H), 5.902 (d, 1H), 6.013 (d, 1H), 7.560 (d, 2H),
8.152 (d, 2H); δC (150 MHz, CD3COCD3): 21.9, 23.9, 54.3,
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64.0, 71.1, 71.5, 72.3, 87.6, 126.0, 132.0, 145.5, 171.8, 171.9
and 207.4. m/z (100% ESI-MS): 485 [M + H]+, 507 [M + Na]+.
2,4-Dinitrophenyl 2-acetamido-2-deoxy-1-thio-3,4,6-tri-O-
acetyl-α-D-glucopyranose (5b). To a solution of compound 426
(500 mg, 1.37 mmol) in 10 ml dichloromethane stirred under a
N2 atmosphere was added 1-fluoro-2,4-dinitrobenzene (173 μl,
1.37 mmol) and triethylamine (230 μl, 1.65 mmol). The mixture
was allowed to stir under a N2 atmosphere for 24 h. The reaction
mixture was then concentrated and the resulting product was
purified using flash chromatography (2% MeOH/CH2Cl2),
resulting in 570 mg (79% yield) of pure 5b as a yellow solid. δH
(300 MHz, CDCl3, Me4Si): 1.935 (s, 3H), 1.991 (s, 3H), 2.034
(s, 3H), 2.066 (s, 3H), 4.043 (dd, 1H), 4.265 (m, 2H), 4.626 (m,
2H), 5.235 (m, 2H), 6.100 (d, 1H), 8.045 (d, 1H), 8.406 (dd,
1H), 9.026 (d, 1H); m/z (100% ESI-MS): 530 [M + H]+.
Benzyl 2-acetamido-2-deoxy-1-thio-3,4,6-tri-O-acetyl-α-D-glu-
copyranose (5c). To a solution of compound 426 (220 mg,
0.61 mmol) in 2 ml dichloromethane stirred under a N2 atmos-
phere was added benzylbromide (87 μl, 0.732 mmol) and tri-
ethylamine (170 μl, 1.22 mmol). The reaction mixture was
allowed to stir under a N2 atmosphere for 24 h. Subsequently the
reaction was concentrated and the resulting product was purified
using flash chromatography (2% MeOH/CH2Cl2), resulting in
170 mg (62% yield) of pure 5c as an off white oil. δH
(400 MHz, CD3OD, Me4Si): 1.89 (s, 3H), 1.93 (s, 3H), 2.01
(s, 3H), 2.06 (s, 3H), 3.81 (d, 2H), 3.98 (d, 1H), 4.24 (dd, 1H),
4.38 (m, 3H), 4.97 (dd, 1H), 5.16 (dd, 1H), 5.29 (d, 1H) and
7.30 (m, 5H). δC (100 MHz, CD3OD, Me4Si): 20.4, 22.1, 35.0,
52.9, 63.1, 69.3, 70.6, 71.9, 83.8, 128.1, 129.4, 129.9, 138.9 and
171.2.
4-Nitrophenyl 2-acetamido-2-deoxy-1-thio-α-D-glucopyranose
(3a). To a solution of 5a (230 mg, 0.475 mmol) in 18 ml of
H2O (19%), MeOH (50%) and acetone (31%), was added 2.3 g
of Amberlite IRA-400 (OH−). The reaction mixture was allowed
to stir for 1 h at ambient temperature. The volatile solvents were
removed in vacuo and the residual aqueous product mixture was
subjected to C18 flash chromatography (50% MeCN/H2O).
Aqueous fractions containing the compound were collected and
dried by lyophilization, resulting in 50 mg (29% yield) of pure
3a as an amorphous yellow solid. δH (300 MHz, CD3OD,
Me4Si): 1.99 (s, 3H), 3.44 (t, 1H), 3.74 (m, 3H), 3.97 (m, 1H),
4.15 (dd, 1H), 6.08 (d, 1H), 7.68 (d, 2H) and 8.15 (d, 2H).
δC (75 MHz, CD3OD, Me4Si): 22.5, 56.1, 62.4, 72.3, 72.6, 75.7,
87.3, 124.9, 130.6, 146.3, 147.5 and 173.9. m/z (100%




nose (3b). Prepared as for 3a from 5b (230 mg, 0.434 mmol),
resulting in 60 mg (34% yield) of 3b as an amorphous yellow
solid. δH (300 MHz, (CD3)2SO2, Me4Si): 1.829 (s, 3H), 3.264
(m, 1H), 3.516 (q, 1H), 3.588 (m, 2H), 3.674 (m, 1H), 3.983 (m,
1H), 4.554 (t, 1H), 5.125 (d, 1H), 5.272 (d, 1H), 6.051 (d, 1H),
8.150 (d, 1H), 8.273 (d, 1H), 8.426 (dd, 1H), 8.818 (d, 1H). m/z




Prepared as for 3a from 5c (230 mg, 0.507 mmol), resulting in
76 mg (38% yield) of 3c. m.p. 192–194 °C (dec). δH (300 MHz,
CD3OD, Me4Si): 1.89 (s, 3H), 3.36 (dd, 1H), 3.60 (dd, 1H),
3.76 (m, 4H), 3.99 (m, 2H), 5.34 (d, 1H), 7.20 (t, 1H), 7.27
(t, 2H) and 7.33 (d, 2H). δC (75 MHz, CD3OD, Me4Si): 22.5,
35.0, 55.6, 62.6, 72.6, 74.5, 84.0, 128.0, 129.4, 130.1, 139.6,




The mshB (Rv1170) gene was amplified from M. tuberculosis
H37Rv genomic DNA using as forward primer 5′-
GGTGCCTC ̲C ̲A̲T ̲G̲G ̲CTGAGACGCCGC-3′ and as reverse
primer 5′-CCTGGTTGGCC ̲T̲C ̲G ̲A̲G ̲CGTGCCGGAC-3′. The
primers respectively contained NcoI and XhoI restriction
enzyme sites (underlined), while the reverse primer also
removed the native stop codon. The resulting PCR product was
treated with NcoI and XhoI and ligated to similarly treated
pET28a(+) to yield the expression vector pET28a(+)-mshB that
encodes recombinant MshB with a C-terminal 6×His-tag. The
plasmid’s sequence was confirmed by DNA sequencing.
For the expression of MshB the pET28a(+)-mshB plasmid
was transformed (heat shock method) into E. coli BL21*(DE3)
cells. LB medium (500 ml) was inoculated with a 5 ml starter
culture of these cells grown in the same medium, followed by
cell growth at 37 °C until the culture reached an OD600 of 0.6.
Expression was induced by the addition of IPTG to a final con-
centration of 0.10 mM, after which the culture was incubated
overnight at 22 °C. Cells were harvested by centrifugation at
17 000 × g for 20 min at 10 °C. The resulting cell pellet was
resuspended in binding buffer (20 mM Tris–HCl, 5 mM imida-
zole, 500 mM NaCl, pH 7.9), and the cells were disrupted using
sonication with external cooling (ice bath). Cell debris were
removed by centrifugation at 75 000 × g for 20 min at 10 °C to
obtain the clarified cell extract used for purification.
The protein was purified using an automated purification
program on an ÄKTAprime system (Amersham Bioscience)
fitted with a 1 ml HiTrap Chelating HP column (GE Healthcare)
pre-loaded with Zn2+. The column-bound MshB was eluted with
100% elution buffer (20 mM Tris-HCl, 500 mM imidazole,
500 mM NaCl, pH 7.9) and desalted using a 5 ml HiTrap desalt-
ing column (GE Healthcare) with gel filtration buffer (25 mM
Tris-HCl, 5 mM MgCl2, 5% glycerol, pH 8) on the ÄKTAprime
system. Protein purity was confirmed with SDS-PAGE analyses
and protein concentration was determined with a Bradford assay.
Pure MshB (in gel filtration buffer with 5% glycerol added) was
aliquoted and stored at −80 °C until needed.
HPLC-based activity analysis
All samples used for the direct HPLC analysis of MshB activity
contained one of the thioglycoside substrates (3a, 3b or 3c) at a
final concentration of 0.1 mM, assay buffer (50 mM HEPES,
50 mM NaCl, <1% DMSO, pH 7.4) and MshB (16.7 μg; 2 μM)
in a total volume of 250 μl. Reactions were initiated with the
addition of MshB. Samples of the reaction were stopped at
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intervals of 5 min over a period of 20 min by heat inactivation,
followed by removal of the denatured enzyme by centrifugation
at 12 000 × g for 5 min to obtain the clarified samples used for
HPLC analysis.
For the determination of the substrate concentrations in the
samples, standard solutions of 3a–c with a concentration range
of 0–120 μM and a final volume of 250 μl each were given the
same treatment as the enzyme reaction samples before these
were also analysed by HPLC. From these results a standard
curve which correlated peak area with concentration was
obtained for each substrate.
Samples of 5 μl each were injected on to a Synergi 4μ Fusion-
RP 250 × 2.00 mm column (Phenomenex) and eluted using
aqueous acetonitrile as solvent. The amount of acetonitrile used
differed for each substrate: for GlcNAc-SPNP (3a), 30% MeCN/
H2O; for GlcNAc-SDNP (3b), 25% MeCN/H2O; and for
GlcNAc-SBn (3c), 40% MeCN/H2O. Separation was monitored
at 320 nm for 3a and 3b, and at 254 nm for 3c.
FSA- and DTNB-based activity analyses
Reaction mixtures (250 μl) containing the respective substrate
(5 mM) in assay buffer (50 mM HEPES, 50 mM NaCl, 1 mM
TCEP, 5–10% DMSO, pH 7.5) and MshB (8.1 μg; 1 μM) were
incubated at 30 °C. Samples (30 μl) of the reaction mixture were
added at 10 min intervals to 10 μl trichloroacetic acid (TCA)
(1.22 M) to quench the reaction, followed by removal of the pre-
cipitated protein by centrifugation at 12 000 × g for 5 min. The
supernatant (25 μl) was subsequently added to 75 μl borate
buffer (1 M, pH 9).
For the fluorescamine (FSA)-based analysis, 49 μl of the
resulting mixture was added to 30 μl of FSA (10 mM) contained
in a 96-well microplate incubated at room temperature, after
which the fluorescence was determined using an excitation wave-
length of 395 nm, and an emission wavelength of 485 nm.
For the 5,5′-dithiobis-(2-nitrobenzoic acid) (DTNB)-based
analysis, 49 μl of the resulting mixture was diluted to 100 μl,
and then added to 30 μl DTNB (2.2 mM) contained in a 96-well
microplate. After incubation at room temperature for 10 min, the
absorbance at 412 nm was determined.
LC-HR-ESI-MS analyses
Reaction mixtures (100 μl) contained GlcNAc-SDNP (3b)
(0.7 mM) in assay buffer (50 mM HEPES, 50 mM NaCl, ∼5%
DMSO, pH 7.5) (the enzyme was omitted from a negative
control reaction). One set of reaction mixtures also contained
1 mM TCEP. Mixtures were equilibrated at 30 °C for 10 min
before MshB (1 μM final concentration) was added, followed by
incubation at 30 °C for 1 h. The reaction was quenched by
adding two 45 μl aliquots from each mixture to two separate
microfuge tubes containing 15 μl TCA (6.12 M) each. The preci-
pitated protein was removed by centrifugation at 12 000 × g for
5 min, after which the supernatants from each tube (37.5 μl)
were added to 112.5 μl borate buffer (1 M, pH 9) contained in
two separate microfuge tubes. The tubes subsequently received
either 45 μl acetonitrile or 45 μl DTNB (0.72 mM in acetonitrile)
prior to LC-HR-ESI-MS analysis.
Reaction mixtures were analysed on a Waters Aquity UPLC
system with an autosampler using a Synergi 4μ Fusion-RP 250 ×
2.00 mm column (Phenomenex). The sample injection volume
was 20 μl and the autosampler syringe was washed with solvent
A (0.1% formic acid in water) before each injection. A gradient
elution program with a flow-rate of 0.30 ml min−1 was used for
the analysis. The gradient was as follows: 0–6 min, linear
increase to 50% solvent B (0.1% formic acid in acetonitrile);
6–8 min, isocratic 50% B; 8–10 min, linear increase to 95%
solvent B. Detection was performed on a Waters Synapt G2
QTOF mass spectrometer. Analytes were detected in the positive
and negative ion mode using a capillary voltage of 3000 V, cone
voltages of 15 V and a source temperature of 150 °C. The
mass spectrometer was calibrated with sodium formate and
Leu-enkephalin as internal standard to acquire the lock mass for
the HR-ESI-MS analysis. Data processing was done using
MassLynx (Waters).
Continuous DTNB-based MshB assay
Reaction mixtures (125 μl) contained GlcNAc-SDNP (3b)
(0–5 mM) in assay buffer (50 mM HEPES, 50 mM NaCl, ∼10%
DMSO, pH 7.5) with DTNB (0.75 mM) and MshB (10 μg;
2.5 μM) were incubated at 30 °C in a 96-well microplate, and
the increase in absorbance at 412 nm was monitored over a
period of 30 min. Reaction rates were determined by linear
regression of the resulting progress curves obtained between
5–30 min. Discontinuous reaction monitoring was performed as
before, using the same reaction mixture without DTNB and with-
drawing 30 μl aliquots at set time intervals for processing and
analysis as described above.
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2.3 Summary of findings  
The results of the FSA-based assays seemed to indicate that GlcNAc-SBn is a better 
substrate for MshB than GlcNAc or either of the other two chromogenic substrates 
(refer to Table 1 in publication, section 2.4). This was in agreement with the result 
obtained by Gammon et al. [8], which showed GlcNAc-SPh to be accepted as an 
alternative MshB substrate. However, when the chromogenic substrates were 
assayed by means of an end-point DTNB derivitization-based assay, MshB was 
found to have a high specific activity for GlcNAc-SDNP. No activity was observed 
with GlcNAc or the other two compounds (refer to Table 1 in publication, section 2.4). 
This led to the discovery of the S→N intramolecular rearrangement of the GlcNAc-
SDNP deacetylated product, and ultimately to the development of the first continuous 
assay of MshB activity. 
Unfortunately, GlcNAc-SDNP is not commercially available, and must be synthesized 
chemically. The yields for its preparation at present are still very low, and it also is 
poorly soluble in water which makes it difficult to handle. The next steps in the assay 
development would therefore be to identify chromogenic compounds that are more 
soluble in water, and to develop simpler, easier method to prepare these compounds. 
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Chapter 3: Engineering of an α-N-
acetylglucosaminidase for biocatalytic 
preparation of thioglycosides as 
alternative substrate of MshB 
3.1 Introduction  
The natural substrate of MshB is GlcNAc-Ins, a pseudo-disaccharide containing 
α(1→1) glycosidic linkage (Figure 2.1, and Section 2.1). GlcNAc-Ins is not 
commercially available, and it is therefore usually obtained by one of two ways: by 
multi-step chemical total synthesis [1-4], or by isolation from natural sources, such as 
from M. smegmatis [5]. However, these methods are not ideal because of the low 
yield of the final product that is obtained in both cases, and because of the time-
consuming nature of obtaining GlcNAc-Ins in this manner. These drawbacks have led 
to numerous investigations and the characterization of various compounds containing 
the GlcNAc-backbone – such as GlcNAc, the GlcNAc S-bimane derivative MsmB and 
the GlcNAc thioglycosides used in the studies described in the previous chapter – as 
alternative substrates for MshB [6]. However, among these compounds the only 
commercially available alternative MshB substrate is the minimal substrate GlcNAc; 
all others must still be prepared by means of chemical synthesis. Unfortunately, 
MshB has been found to have both low activity and affinity for GlcNAc as compared 
to its natural or other alternative substrates, making it not ideal for use in the 
assaying of MshB activity [6-8].  
In light of these shortcomings, the main focus of the studies described in this chapter 
was to engineer an -N-acetylglucosaminidase enzyme to transform it into a 
biocatalyst that could be used to synthesize the natural or alternative substrates of 
MshB. These studies were performed in collaboration with Dr. Marco Moracci of the 
Institute of Protein Biochemistry (IPB) of the National Research Council (NRC) of 
Italy in Naples, and some of the results described here were obtained during a 
month-long research visit to his laboratory.  
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3.2 Strategy for the biocatalytic preparation of MshB substrate 
analogues 
Various strategies have been developed for the preparation of biocatalysts that can 
be used for the synthesis of di- or oligosaccharides from suitably activated 
precursors. In all cases, these biocatalysts are based on naturally-occurring 
glycosidase (glycoside hydrolase) enzymes, which are subsequently mutated to 
introduce the desired reactivity. This section provides an introduction to these 
strategies.  
 
3.2.1 Glycosidases and their catalytic mechanism 
Glycosidases, also known as glycoside hydrolases, are catabolic enzymes that 
hydrolyze the glycosidic bond(s) of oligosaccharides or polysaccharides into their 
constituent sugar molecules [9]. They can act on both α- and β-glycosidic bonds, and 
can do so by endo-acting hydrolysis or exo-acting hydrolysis [10]. The resulting 
cleavage of the glycosidic bond happens with either net retention or net inversion of 
the anomeric configuration. It is this stereochemical course of the reaction that is 
used to classify the glycosidases as either inverting or retaining enzymes (Figure 3.1) 
[9-13]. 
 
Fig. 3.1: Catalytic mechanisms of glycosidase. Figure adapted from Perugino et al. 
[13]. 
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Inverting and retaining glycosidases share some common characteristics in their 
mechanisms and active site residues: they both contain an oxocarbenium ion-like 
transitions state and a pair of carboxylic acid-containing active site residues  [9, 11]. 
However, inverting glycosidase enzymes use a direct displacement mechanism in 
which one active site residue acts as a base deprotonating the water molecule acting 
as a nucleophile, while the other residue acts as an acid that protonates the leaving 
group Figure 3.1A). Retaining glycosidases on the other hand utilizes a double 
displacement mechanism that consists of a glycosylation step in which the one sugar 
moiety is transferred to the enzyme, followed by deglycosylation which involves the 
hydrolysis of the glycosyl-enzyme intermediate through an oxocarbenium ion-like 
transition state to liberate the sugar molecules (Figure 3.1B) [9]. In this mechanism, 
the one carboxylic acid residue acts as a nucleophile that reacts with the anomeric 
carbon atom to form the covalent glycosyl-enzyme intermediate, while the other 
residue acts as an acid catalyst to cleave the glycosidic bond. This same residue 
subsequently acts as a base in the following attack by an incoming water molecule 
on the anomeric site to liberate the sugar molecule from the glycosyl-enzyme 
intermediate. This difference in mechanism is made possible by the active site 
residues of inverting glycosidases being far apart from each other compared to those 
of retaining glycosidases, which makes the intervention of a water molecule possible 
[11]. 
Glycosidases are also involved in an anabolic process called glycoside synthesis. 
Glycoside synthesis can occur either by one of two different mechanisms: by a 
reverse hydrolysis reaction, or by transglycosylation [13, 14]. Transglycosylation 
involves the replacement of water molecule with a different sugar molecule to 
promote synthesis [12]. However, the anabolic process of glycoside synthesis has its 
own limitations, as the end products of the reaction can act as substrates for the 
hydrolase activity of the enzyme, which results in low yield of the final product. 
 
3.2.2 Converting glycosidase enzymes into glycosynthases 
One strategy to overcome the problems associated with the anabolic process of 
glycoside synthesis is to mutate the glycosidase enzymes to transform them into 
glycosynthases. This is the first strategy that can be used to convert glycosidases 
into useful biocatalysts. Glycosynthases are prepared by mutating the active site 
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nucleophile residue of the glycosidase enzyme so that the first catalytic step of the 
hydrolysis reaction cannot take place [13, 15]. Such gycosynthases require a 
glycosyl donor with a good leaving group (such as fluoride, 2- or 4-nitrophenolate or 
2,4-dinitrophenolate) to carry out the transglycosylation step (Figure 3.2).  
 
Fig. 3.2: The mechanism of β-glycosynthases generated from a β-retaining 
glycosidase. Figure adapted from Perugino et al. [13] 
 
When an activated glycosyl donor is used with an anomeric configuration that is 
inverted relative to that of the normal substrate of the parent glycosidase, the 
glycosynthase acts as an inverting glycosynthase: the glycosyl donor acts as the 
intermediate of the reaction (Figure 3.2A) [13]. In order for the glycosynthase to act 
as a retaining glycosynthase, an activated glycosyl donor with the same anomeric 
configuration as the normal substrate must be used, as well as an additional external 
nucleophile, such as azide or formate (Figure 3.2B). In this case, the added external 
nucleophile mimics the role of the mutated nucleophile active site residue. This is 
followed by the attack of an acceptor molecule on the external nucleophile-substrate 
intermediate, which is assisted by the acid/base residue that now acts as a base.  
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The first glycosynthase was derived from the β-retaining glycosidase of 
Agrobacterium faecalis (Agrobacterium sp.) by Withers and co-workers in 1998 [16], 
wherein they mutated the nucleophile Glu358 to Ala. In an attempt to increase the 
activity of the glycosynthase, these researchers also mutated the nucleopile of an 
Agrobacterium sp. glycosidase (Glu358) to Cys, Ser, Asp or Gly [15]. They found that 
Ser and Gly showed improved activity compared to the other mutations, with the Gly 
mutant showing the best activity overall. Since the discovery by Withers and co-
workers [16] many glycosidases have been engineered using the same approach to 
obtain glycosynthases which are based on the retaining glycosidases. Most of the 
glycosynthases available to date are derived from β-retaining glycosidases of 
different microorganisms with only a few of α-retaining glycosidases modified to α-
glycosynthase [13, 15, 17, 18]. The first α-glycosynthase was derived from the α-
glucosidases of Schizosaccharomyces pombe by Chiba and co-workers in 2002 [19].  
 
3.2.3 Converting glycosidase enzymes into thioglycoligases 
A second strategy for the conversion of glycosidase enzymes into biocatalysts is 
based on the preparation of thioglycoligases. Thioglycoligases are formed by 
mutating the acid/base active site residue of a glycosidase to a non-catalytic residue, 
and using thiol-containing molecules as glycoside acceptors for the synthesis of 
thioglycosides [20-22]. Thioglycosides are glycans that contain a sulphur atom at the 
anomeric position instead of oxygen [21]. They are very stable in the presence of the 
glycosidase enzymes, as they are not natural substrates for the hydrolysis reaction 
catalysed by these enzymes [22]. While glycosynthases require either an activated 
substrate donor with an opposite anomeric configuration, or reactivation with an 
external nucleophile substrate, thioglycoligases only require a substrate donor with a 
good leaving group such as 2,4-dinitrophenolate (DNP) and a thiosugar molecule as 
an acceptor to carry out the thioglycoligase reaction (Figure 3.3) [20-23].  
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Fig. 3.3: The mechanism of thioglycoligase. Figure adapted from Perugino et al. [13]. 
 
Glycosidases were first modified to thioglycoligases by Withers and co-workers in 
2003 [21]. They mutated the acid/base residue of the β-glycosidases from 
Agrobacterium sp. and Cellulomonas fimi (C. fimi )to Ala, and used 2,4-dinitrophenyl 
β-D-glucopyranoside and 2,5-dinitrophenyl β-D-mannopyranoside respectively for 
each enzyme as substrate donors, and para-nitrophenyl 4-deoxy-4-thio-β-D-
mannopyranoside or para-nitrophenyl 4-deoxy-4-thio-β-D-xylopyranoside as acceptor 
molecules to demonstrate the concept of thioglycoligase-mediated synthesis. They 
incubated the mutants with the respective substrate donor and the acceptor molecule 
for a certain time at room temperature, and followed the reaction by thin layer 
chromatography (TLC) analysis of the reaction products, 1H and 13C NMR 
spectroscopy and mass spectrometry. The analyses showed the formation of 
disaccharide molecules that contained a sulphur-linked glycosidic bonds. However, 
when they used the parent sugar molecules of the wild type enzyme, i.e. para-
nitrophenyl β-D-xylopyranoside and para-nitrophenyl β-D-glucopyranoside for 
Agrobacterium sp. and C. fimi respectively as acceptor molecules, no enzymatic 
reaction products was formed for the Agrobacterium sp. mutants. On the other hand 
C. fimi mutant was found to form a disaccharide molecule very slowly. This result 
confirmed that the glycosidases had been converted to thioglycoligases. To date four 
β-glycosidases and three α-glycosidases have been modified to thioglycoligases [17].  
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3.2.4 Converting a glycosidase into a suitable biocatalyst for the 
preparation of MshB substrate analogues 
The α-N-acetylglucosaminidase from the Gram-positive anaerobic and heat-resistant 
endospore-forming bacterium, Clostridium perfringens (ATCC 13124), was identified 
as the potential candidate for the generation of a suitable biocatalyst for the 
preparation of MshB substrate analogue. The amino acid sequence of this enzyme, 
also known as CpGH89, was found to be about 30% related to the human α-N-
acetylglucosaminidase (NAGLU). Both CpGH89 and NAGLU are classified as 
belonging to glycoside hydrolase family 89 (GH89), and act as retaining glycosidases 
that catalyze the hydrolysis of α-N-acetylglucosamine-containing oligosaccharides. 
The structure and mechanism of this enzyme was reported by Ficko-Blean et. al. [24] 
in 2008, wherein they showed that CpGH89 consist of four distinct domains: an N-
terminal domain, a linking α/β domain, a core (α/β)8 barrel and a C-terminal domain. 
The core (α/β)8 barrel (residues 280 to 620) was found to contain the active site 
which is in the shape of a sock formed by aromatic amino acids, with Glu483 acting 
as the acid/base residue and Glu601 as the nucleophilic active site residue.  
Based on the previously described strategies for the conversion glycosidases into 
biocatalysts, two options were considered for the engineering of a biocatalyst that will 
enable the biocatalytic preparation of natural and/or alternative MshB substrates: 
Option 1: Convert CpGH89 into an α-glycosynthase for preparation of α-GlcNAc-
containing glycosides.  
In this approach an α-glycosynthase is generated from CpGH89 by mutating the 
nucleophilic active site residue Glu601 to the non-reactive residues Gly, Ala or Ser. 
The generated α-glycosynthase can then be used to produce sugar molecules such 
as GlcNAc-Ins and the GlcNAc glycosides of 1,2,3-trihydroxycyclohexane and benzyl 
alcohol among others, by using either an inverting or retaining mechanism approach, 
as shown in figure 3.4. In the inverting mechanism, an activated β-glycosyl donor 
molecule will be used with the various acceptor molecules (R1) to generate an α-
glycosidic bond, while for the retaining mechanism an activated α-glycosyl donor 
molecule, external nucleophile (which mimics the mutated nucleophile) and various 
acceptor molecules will be utilized to form products with an α-glycosidic bond.  
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Fig. 3.4: The proposed approach for the synthesis of α-GlcNAc-containing glycosides 
using an α-glycosynthase. Panel A: For an inverting glycosynthase an activated β-
glycosyl donor molecule is used together with various sugar acceptor molecules to 
retain the configuration of the α-glycosidic bond. Panel B: For a retaining 
glycosynthase, an activated α-glycosyl donor molecule is used together with various 
sugar acceptor molecules and an external nucleophile (to mimic the mutated 
nucleophile) to form products with an α-glycosidic bond. 
 
The advantage of the using the glycosynthase approach is that it will allow for the 
preparation of the natural substrate of MshB (GlcNAc-Ins). However, it requires the 
use of either an activated β-GlcNAc glycosyl donor, which is difficult to chemically 
synthesize, for the inverting glycosynthase (Figure 3.1A), or the challenging 
reactivation of the glycosynthase with an external nucleophile if the α-retaining 
glycosynthase approach were to be used (Figure 3.1B). 
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Option 2: Convert CpGH89 into an α-thioglycoligase as a biocatalyst for preparation 
of GlcNAc-containing thioglycosides. 
In this approach α-thioglycoligases are generated from CpGH89 by mutating the 
acid/base active site residue Glu483 to the non-reactive residues Gln, Ala or Ser. The 
generated α-thioglycoligases will be used to produce thiosugar molecules such as 
GlcNAc-SDNP and the GlcNAc thioglycosides of cyclohexanethiol, benzenethiol and 
p-nitrophenyl 4-thioglucopyranoside among others, by using a retaining mechanism 
approach as shown in figure 3.5. An activated α-glycosyl donor molecule together 
with various thio-acceptor molecules (R2) will be used to form GlcNAc-based α-
thioglycosides.  
 
Fig. 3.5 The proposed approach to for the synthesis of α-GlcNAc-containing 
thioglycosides using an α-thioglycoligase. For a retaining thioglycosides, an activated 
α-glycosyl donor molecule is used together with various thiol-containing acceptor 
molecules to generate GlcNAc-based α-thioglycosides.  
 
The benefit of the thioglycoligase approach is that an α-GlcNAc glycosyl donor is 
used; several such donors are commercially available. Furthermore, no external 
nucleophile is required, since the thiol group of the thiosugar acceptor reacts as the 
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nucleophile. However, a shortcoming is that thiosugars are not commercially 
available, and must be prepared through chemical synthesis. 
For this study, it was decided to follow Option 2 and to prepare a thioglycoligase 
catalyst. However, attempts at preparing a glycosynthase (Option 1) were 
simultaneously initiated by our collaborator, Dr. Moracci of the IPB, Naples, Italy. 
3.3 Results  
3.3.1 Generation of plasmids encoding CpGH89 mutants  
An acid/base catalyst mutant library was generated by site-directed mutagenesis and 
single overlap extension (SOE) Polymerase Chain Reaction (PCR) using a plasmid 
containing the native cpgh89 gene, which encodes the α-N-acetlyglucosaminidase of 
Clostridium perfringens, as template. The acid/base catalyst site Glu483 was 
mutated to Gln, Ala and Ser residues. The expression vectors generated were 
named pET28a(+)-CpGH89E483Q, pET28a(+)-CpGH89E483A and pET28a(+)-
CpGH89E483S for the Glu, Ala and Ser mutants respectively. The modification was 
confirmed by DNA sequencing as shown in figure 3.6, wherein the conflict, which 
indicates the mutations, can clearly be seen: the genetic codes (GAA) which encodes 
for the Glu483 of the wild type was modified into CAA, GCA and TCA for generation of 
the various mutants. 
 
Fig. 3.6: DNA sequence alignments of the various mutants created from the wild type 
sequence. The genetic code GA is changed to CA, GC and TC for various mutants. 
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3.3.2 Expression and purification of wild type and mutant CpGH89 
proteins 
The CpGH89 enzymes were expressed from the pET28a(+) constructs, which 
encodes proteins with N-terminal 6xHis-tags, transformed into Escherichia coli (E. 
coli) BL21 (DE3). The expression conditions previously reported by Ficko-Blean et al. 
were used [24]. The proteins were purified by immobilized-metal affinity 
chromatography (IMAC) using an ÄKTA prime system. Cell crude extracts were 
applied to a 1 mL HiTrap Chelating HP column preloaded with Ni2+, followed by 
stepwise elution using imidazole concentrations of between 25 and 150 mM (Figure 
3.7A). The elution profile was monitored at 280 nm, which allowed the purification of 
the proteins to heterogeneity. The purity of the samples was confirmed by 12% 
sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE). A typical 
gel analysis of the heterologously expressed and purified proteins, which has a 
predicted molecular weight of 99 kDa, is shown in Figure 3.7B.  
 
    
Fig. 3.7:  Purification of the protein and nalyses of protein purification results by 12% 
SDS-PAGE.  
A: Chromatography of the purification of proteins by IMAC using ÄKTA prime system 
following a stepwise elution using different concentration of imidazole. E1: Elution at 
25 mM of imidazole and E2 elution at 150 mM of imidazole.  
B: Analysis of purification by 12% SDS-PAGE. Lane 1-4 are proteins fraction eluted 
at E1: lane 1 CpGH89, lane 2 CpGH89E483Q, lane 3 CpGH89E483A, lane 4 
CpGH89E483S and lane 6-9 are proteins fraction eluted at E2:lane 6 CpGH89, lane 
7 CpGH89E483Q, lane 8 CpGH89E483A, lane 9 CpGH89E483S. Lane 5 is the 
PageRuler™ unstained protein marker.  
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3.3.3 Thermal stability of wild type and mutant CpGH89 proteins  
The secondary structure of CpGH89 is made up of α-helix and β-sheets, and it 
contains four distinct domains (N-terminal, linking α/β, core (α/β)8 barrel and C-
terminal) [24]. Replacement of the Glu483 with Gln, Ala and Ser might influence the 
secondary and tertiary structure of the protein, leading to misfolding. To verify if the 
modification of Glu483 did not influence the folding of the protein, thermal stability of 
the protein was tested using circular dichroism (CD), which monitors the secondary 
structure of the protein. The stability of the mutants was established by monitoring 
the temperature-dependent melting curves with CD at 220 nm. No differences in the 
stability of the protein were observed (Figure 3.8). All the mutants’ protein had the 
same melting temperature of ± 700C, while the wild type started denaturing at about 
30C higher temperature (± 730C) than the mutants. In addition, all the mutants and 
wild type protein seemed to have a structural conformation change around ± 530C. 
 
 
Fig. 3.8: The CD analysis of CpGH89 and its mutants. A: CD spectra of the buffer, 
wild type and its mutants at 25oC over a range of wavelengths (200-260nm). B: 
Melting curves of CpGH89 and its mutants measured at 220 nm between 25-85oC at 
an interval of 1 min per 1oC change in temperature.  
 
3.3.4 Hydrolytic activity of wild type and mutant CpGH89 proteins   
The α-glycosidase CpGH89 utilizes the retaining mechanism for hydrolysis, with 
Glu601 acting as the nucleophile and Glu483 as the acid/base residue [24]. This 
means modification of any of the catalytic residues should result in the loss of 
hydrolysis activity. The hydrolytic activity of the three different CpGH89 mutants and 
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the wild type enzyme were tested with two α-substrates: p-nitrophenyl α-N-acetyl-D-
glucosaminide (pNP-α-GlcNAc) and o-nitrophenyl α-N-acetyl-D-glucosaminide (oNP-
α-GlcNAc) (Figure 3.9). The hydrolysis of these compounds (pNP-α-GlcNAc and 
oNP-α-GlcNAc) by the enzyme liberate GlcNAc and 4-nitrophenol (pNP) or 2-
nitrophenol (oNP). The liberation of pNP and oNP produces a yellow colour at high 
pH which can be detected spectrophotometrically at 400 nm, with extinction 
coefficients of 13300 M-1cm-1 and 1800 M-1cm-1 respectively in 0.1M sodium 
phosphate buffer at pH 7.3.  
 
 
Fig. 3.9: The hydrolytic activity assay used to test the catalytic activity for CpGH89 
and its mutants.  
 
The mutants’ (CpGH89E483Q, CpGH89E483A and CpGH89E483S) hydrolytic 
activity was found to be very low in comparison to the activity of the wild type enzyme 
as shown by the Michaelis-Menten plots in figure 3.10. The kcat-values of the mutants 
were more than 10-fold smaller than that measured for the wild type enzyme, which 
clearly shows that these proteins have lost their hydrolytic activity (Table 3.1). This 
confirms the importance of the Glu483 for hydrolytic activity.  The CpGH89E483Q 
protein had the lowest turnover for substrates with kcat = (6.2 ± 0.1)×10
-3 sec-1 for 
GlcNAc-pNP and (3.3 ± 0.1)×10-2 sec-1 for GlcNAc-oNP. CpGH89E483A and 
CpGH89E483S showed similar turnover for the different substrates, with their kcat 
values being higher than that shown by CpGH89E483Q (Table 3.1).  
 






















































Fig. 3.10: Kinetic characterisation of the CpGH89 and its mutants. The graphs were 
plotted using non-linear fitting of the Michaelis-Menten equation 
(Vmax=kcat.[S]/KM+[S]) to the obtained data with the best-fit represented by the solid 
lines. Each point was done in triplicate with error bars. Panel A: Kinetic 
characterization of CpGH89 and its mutants with GlcNAc-pNP as substrate. Panel B: 
Kinetic characterization of CpGH89 and its mutants with GlcNAc-oNP as substrate.  
 
Table 3.1: The kinetic parameters of the CpGH89 wild type and its mutants 

















GlcNAc-pNP     
CpGH89wt 1.0 ± 0.1 (8.4 ± 0.3)×10-2 (1.7 ± 0.1)×10-1 (1.6 ± 0.8)×10-1 
CpGH89E483Q (2.4 ± 0.2)×10-1 (3.1 ± 0.1)×10-3 (6.2 ± 0.1)×10-3 (2.6 ± 0.7)×10-2 
CpGH89E483A (4.6 ± 0.4)×10-1 (6.5 ± 0.2)×10-3 (1.3 ± 0.0)×10-2 (2.8 ± 0.9)×10-2 
CpGH89E483S (4.4 ± 0.3)×10-1 (7.9 ± 0.2)×10-3 (1.6 ± 0.0)×10-2 (3.6 ± 1.6)×10-2 
GlcNAc-oNP     
CpGH89wt (4.2 ± 0.6)×10-1 1.2 ± 0.1 2.3 ± 0.1 5.6 ± 2.0 
CpGH89E483Q (1.1 ± 0.5)×10-2 (1.6 ± 0.0)×10-2 (3.3 ± 0.1)×10-2 3.1 ± 0.2 
CpGH89E483A (4.6 ± 0.5)×10-2 (3.8 ± 0.0)×10-2 (7.6 ± 0.1)×10-2 1.7 ± 0.0 
CpGH89E483S (3.4 ± 0.5)×10-2 (3.2 ± 0.0)×10-2 (6.4 ± 0.1)×10-2 1.9 ± 0.3 
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3.3.5 Evaluation of the thioglycoligase ability of the mutants 
To test whether the various mutants can promote transglycosylation, 2,4-
dinitrophenyl α-N-acetyl-D-glucosaminide (DNP-α-GlcNAc) was used as the donor 
substrate, while sodium azide (NaN3) was used as the nucleophile to mimic the role 
of the thiosugar. NaN3 was used for this first test to determine if the active site can 
accommodate an external nucleophole, and because no thiosugar is commercially 
available, and will have to be synthesized first before it can be used in such tests.  
DNP-α-GlcNAc was chosen as the substrate donor because the pKa value of its 
leaving group (2,4-dinitrophenolate, DNP) is low (3.96) compared to those of pNP-α-
GlcNAc and oNP-α-GlcNAc (~pKa 7.18), indicating that it should have a better 
leaving group ability. DNP-α-GlcNAc was not used to test for the hydrolytic activity of 
the mutants because it is not commercially available and must be prepared by 
chemical synthesis. For this study, it was prepared by Dr. Emiliano Bedini, 
collaborator of Dr. Moracci. 
 
 
Fig. 3.11: The catalytic mechanism of the retaining α-thioglycoligases, CpGH89 
mutant enzymes. Mutation of the acid-based residue allows the glycosyl-enzyme 
intermediate to be formed by reaction of the active site nucleophile with the activated 
donor DNP-α-GlcNAc. If the intermediate is formed, and external nucleophile such as 
NaN3 can react with it to demonstrate its potential to react with thiosugars.  
 
DNP-α-GlcNAc (5 mM), 0.017-0.275 mg/mL of mutations and 100 mM of NaN3 in 100 
mM sodium phosphate buffer, pH 7.3, were incubated at 370C overnight followed by 
TLC analysis of the reaction products. The TLC analysis revealed the formation of at 
least three distinct products for the reactions where the mutant enzymes, 
CpGH89E483Q, CpGH89E483A and CpGH89E483S that is  R4+, R5+ and R6+ 
respectively in Figure 3.11, were incubated in the presence of NaN3. Only two 
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products were observed following the reaction for the reactions with the wild type 
enzyme and the reactions with the other mutants in the absence of NaN3 ( R1-, R2-, 
R3-, R4-, R5-,R6-) and present of NaN3 (R1+, R2+ and R3+) , and only one 
compound (single spot) was observed for the negative controls reaction (R7+ and 
R7- in Figure 3.11). The products spot for R4+, R5+ and R6+ with the highest 
retardation factor (Rf) of 0.88 was only visible under ultraviolet (UV) light, while the 
other two products spot, Rf 0.77 and 0.32,  were visible when stained with 10% 
sulphuric acid in methanol. The products spot with Rf 0.88 is 2,4-dinitrophenol, while 
the middle Rf-value 0.77 had more or less the same Rf-value measured for STD2 (β-
GlcNAc-N3) (Figure 3.11). The Rf-value of the bottom spot was below to that of 
GlcNAc (STD1).  
 
The products spot with Rf 0.77 was only observed in the reactions with NaN3 which 
were catalysed by CpGH89E483Q, CpGH89E483A and CpGH89E483S mutants. 
This indicates that these proteins are able to promote transglycosylation in the 
presence of NaN3. No transglycosylation reaction was observed in the absence or 
presence of NaN3 for reactions catalysed by CpGH89E483G and CpGH89E601G 
(CpGH89E601G mutant is a potential α-glycosynthase created in Dr. M. Moracci lab 
by mutating the nucleophilic active site residue Glu601 to Gly, and was added to this 
test for comparison). The observed products spots for both these enzymes had the 
same Rf-values as the ones obtained for the reactions catalysed by the wild type 
enzyme. This could mean that the replacement of Glu with Gly promotes folding of 
the protein in such a way that another amino acid residue is revealed which then acts 
as a nucleophile promoting hydrolysis. However, for the other α-thioglycoligases (in 
which the acid/base residue was mutated to residues other than Gly) this does not 
occur, indicating that these enzymes have the potential to be used as biocatalysts. 
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Fig. 3.11: TLC analysis of the thioglycoligase ability of the CpGH89 mutants. The 
lanes are identified as follows: STD1, 10 μL of 20 mM GlcNAc and 5μL of 30 mM 
DNP-α-GlcNAc; STD2, 5 μL of 20 mM β-GlcNAcN3;  
R1+/-, CpGH89 wild type with and without NaN3;  
R2+/-, CpGH89E601G with and without NaN3;  
R3+/-, CpGH89E483G with and without NaN3;  
R4+/-, CpGH89E483Q with NaN3 and without NaN3;  
R5+/-, CpGH89E483A with and without NaN3; 
R6+/-, CpGH89E483S with and without NaN3;  
R7+/-, no enzyme with and without NaN3 (negative control).  
The red circles indicate the products/reactants spots visualised by UV light, while the 
brown products/reactants spots were visible after staining with 10% sulphuric acid in 
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3.4 Discussion 
The use of thioglycosides as therapeutic drugs instead of glycosides has increasingly 
been investigated over the past few years [21]. However, to produce thioglycosides a 
new enzymatic approach for their synthesis is needed. This has led to the 
engineering of several glycosidases to thioglycoligases through the removal of the 
acid-base catalytic residue by site-directed mutagenesis [17, 21], with most of the 
thioglycoligases created to date being modified from β-retaining glycosidases from 
microorganisms such as Agrobacterium sp., C. fimi and Bacillus circulans [17]. 
 
In this chapter the cloning, heterologous expression and IMAC purification of new 
potential α-thioglycoligases from a retaining α-glycosidase, the α-N-
acetlyglucosaminidase of C. perfringens, were described. Three potential α-
thioglycoligases were generated through site-directed mutagenesis of the acid/base 
residue (Glu483) using SOE PCR and subsequent expression from the resulting 
plasmids. Previously identified expression parameters that were used to produce the 
wild type allowed for over-expression of the mutant proteins in large quantity [24, 25]. 
The resulting enzymes were found to have a thermal stability similar to that of the 
wild type enzyme, indicating that the mutations did not influence the overall structure 
or folding of the mutant proteins (Figure 3.8).  
 
2,4-Dinitrophenol-containing donors have been reported to be better substrates for 
thioglycoligase reactions than the corresponding p-nitrophenol or o-nitrophenol 
substrates due to the better leaving group ability of 2,4-dinitrophenolate [23]. In the 
case of the CpGH89 mutants, an ideal situation would have been to conduct all tests 
using DNP-α-GlcNAc. However, since it is not commercially available and it is 
produced in low yield by chemical synthesis, the residual hydrolytic activity of the 
mutants could not be tested with this compound as a substrate. Nevertheless, the 
hydrolytic activities of the mutants were measured using pNP-α-GlcNAc and oNP-α-
GlcNAc. The CpGH89 mutants’ hydrolytic activity rates were found to be less than 
95-fold as compared to that of the wild type enzyme (Figure 3.10). These results 
confirm those obtained by Ficko-Blean et. al, [24] in which they discovered the 
catalytic active site residue of CpGH89 to be Glu601 and Glu483.  
 
The generated α-thioglycoligases (CpGH89E483Q, CpGH89E483A and 
CpGH89E483S) were found to be good candidates to use as α-thioglycoligase for the 
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synthesis of α-thioglycosides. Transglycosylation was promoted by the α-
thioglycoligases in the presence of NaN3 (Figure 3.11). This shows that 
CpGH89E483Q, CpGH89E483A and CpGH89E483S are able to catalyse the 
formation of the glycosyl-enzymes intermediate (glycosylation step) which is 
essential for deglycosylation to take place. However, it was quite surprising that the 
CpGH89E483G mutant did not show transglycosylation, but instead only showed 
hydrolysis, both in presence and absence of NaN3. This could indicate that NaN3 is 
unable to resolve the glycosyl-enzyme intermediate, or that the mutation is interfering 
with the formation of glycosyl-enzyme intermediate.  
3.5 Conclusion 
In this study the first examples of α-thioglycoligases from an α-N-
acetylglucosaminidase of C. perfringens were engineered by mutation of the 
enzyme’s acid/base active site residue. All three enzymes were found to be good 
candidates for the enzymatic synthesis of α-thioglycosides which can be used as 
alternative substrate for MshB. Future studies include chemical synthesis of 
thiosugar molecules as acceptor in order to validation the α-thioglycoligase ability 
and the implementation of these enzymes for the large production of a range of MSH 
analogs. These analogs will be evaluated as potential alternative substrate for MshB. 
In addition they will also be evaluated as potential alternative substrate/inhibitors 
compounds against the enzymes involved in the MSH biosynthesis pathway and also 
against the MSH-dependent enzymes. 
3.6 Experimental procedures 
All the chemicals used and columns for the ÄKTAprime system were purchased from 
Sigma-Aldrich unless stated otherwise. All restriction enzymes and the Eppendorf 
Perfectprep® Gel Cleanup kit were purchased from Fermentas. The DNA primers, 
DNA sequencing and ZyppyTM plasmid Miniprep Kit (Zymo Research) was purchased 
from Inqaba Biotechnical Industries (Pty) Ltd. The expression plasmid were obtained 
from Novagen, while the ligation kit was from New England BioLabs. The pET28a(+)-
CpGH89 plasmid, containing the optimized DNA sequence of α-N-
acetylglucosaminidase, was obtained from Dr. Marco Moracci. 
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3.6.1 Generation of the various thioglycoligases  
3.6.1.1 Site-direct mutagenesis  
The pET28a(+)-Cpgh89 plasmid was used as DNA template in all PCR reactions. 
Single overlap extension (SOE) Polymerase Chain Reaction (PCR) was used to 
generate the site mutation into Cpgh89 gene. The primers used to generate the three 
different isoforms are listed in Table 3.2.  
The following PCR conditions were used to generation the DNA fragments consisting 
of the mutants; 10x Pfu buffer without MgSO4, 1.25 U of Pfu DNA polymerase, 
between 2-4 mM of MgSO4, 0.4 mM of dNTPs cocktail, 1 ng of the template DNA 
(pET28a(+)-Cpgh89 optimized plasmid), 1 mM of non-mutagenic/mutagenic forward 
primer and 1 mM of non-mutagenic/mutagenic reverse primer in a total volume of 25 
µL. The void volume was filled with sterilized distilled water. The thermal cycling 
conditions used are shown in Table 3.3. 
 
Table 3.2: DNA sequence of the primers used to generate various mutants of 
CpGH89 














T7 promoter  5’-TAATACGACTCACTATAGGG-3’ 
T7 terminator 5’-GCTAGTTATTGCTCAGCGG-3’ 
 
Table 3.3: Thermal cycling conditions for PCR 
Step Temperature in 0C Time in seconds Number of cycles 
Initialization  94 120 1 
Denaturation 94 30  
30 Annealing 45 30 
Elongation 68 150 
Final elongation 68 360 1 
Final hold 4 Infinite  None  
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The PCR products were analysed by gel electrophoresis (1% agarose gel) stained 
with SYBR®safe and compared to marker (2-log ladder marker) to identify the correct 
size band. The most concentrated bands of the correct size (1754bp) were purified 
from the gel using the Eppendorf Perfectprep® Gel Cleanup kit. The purified PCR 
products were amplified again using the non-mutagenic primers (T7 primers) to link 
the DNA fragments in the same manner as described above. The PCR products 
(2703bp) were analysed and purified as before. 
 
3.6.1.2 Cloning of the PCR products into the plasmid pET28a(+) vector 
Restriction digest of the PCR products and plasmid. Fastdigest NheI and XhoI 
restriction enzymes, were used to generate sticky ends in pET28a(+) and the PCR 
products using the following digestion reaction conditions:  1 U of NheI, 1 U of XhoI 
and 1× Fastdigest buffer and DNA fragments/plasmid to a total volume of 20 µl. The 
reaction mixtures were incubated at 37oC for 1 hour. The digested products were 
visualized by gel electrophoresis and purified as before. 
 
DNA ligation and screening. All constructs were cloned into pET28a(+) (Novagen) 
which contains an N-terminal 6×His-tag and a T7 promoter for heterologous protein 
expression in E. coli. The PCR products to plasmid recombinant ratio were 1:1. For 
the ligation reaction 10 U of T4 DNA Quickligase (New England BioLabs) in 1× Quick 
ligase buffer was added to the predetermined amount of PCR product and plasmid 
and incubated at 25oC for 20 minutes. The ligation reactions were transformed as is 
into chemically competent E. coli MachI cells, plated on Luria Bertani agar media 
containing 30 mg/L kanamycin and incubated at 37oC overnight. The insertion of the 
PCR products into the plasmids pET28a(+) vector was verified by screening the 
colonies using the Colony Fast Screen kit from Epicentre wherein a smear of a 
colony was added to 25 µL of Epilyse solution 1 (30 mM Tris-HCl, pH 8.0, 5 mM 
Na2EDTA, 50 mM NaCl, 20 % sucrose, 0.047 µg.mL
-1 lysozyme and 0.047 µg.mL-1 
RNAse). After the addition 10 µL of Epilyse solution 2 (1× TAE, 2% SDS, 5% sucrose 
and 2 mg.mL-1 bromophenol blue) the mixture was analysed by gel electrophoresis 
as before in comparison to undigested parent pET28a(+) plasmid (plasmids in which 
the PCR products have been inserted should be larger than the parents plasmid). 
Positive screening results were confirmed by diagnostic digests of the constructs with 
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the restriction enzymes used to generate the sticky ends for ligation and by 
sequencing.  
 
3.6.2 Expression of CpGH89 wild type and mutants 
All expressions were done from E. coli BL21 (DE3). The expressing conditions were 
based on the procedure used by Ficko-Blean et al. [25], but with minor modifications. 
The cultures were grown until the optical density at 600nm (OD600) reached 0.600. 
After induction at 37oC with 0.33 mM isopropyl-1-thio-β-D-galactropyranoside (IPTG), 
the cultures were grown overnight before being harvested by centrifugation at 
17600×g for 20 minutes at 10oC. The pellets cells were stored at -20oC until use. 
 
3.6.3 Protein purification  
The cells were resuspended in binding buffer (10 mL of buffer for every gram of dry 
pellet) consisting of 20 mM Tris-HCl, pH 7.9, 5 mM imidazole, 500 mM NaCl, and 
0.05 % (w/v) NaN3 and lysed by sonication. The pellet debris was pelleted by 
centrifugation at 75000×g for 20 minutes at 10oC and the lysate was filtered with a 
Acrodisc PSF Gx/GHP 0.45 μm filter (Pall) prior to injection into the ÄKTA prime 
system for IMAC purification. The supernatant was loaded onto a 1 mL HiTrap 
Chelating HP column preloaded with Ni2+. The bound proteins were eluted by using a 
His-tagged elution buffer (20 mM Tris-HCl, pH 7.9, 500 mM imidazole, 500 mM NaCl, 
and 0.05% (w/v) NaN3) in a step elution between 25 and 150 mM of imidazole 
concentrations. The elution profile was followed by UV at 280 nm. The high salt 
concentration from the eluted proteins was removed by buffer exchange on the on 
the ÄKTA prime system using a 5 mL HiTrap desalting column and gel filtration buffer 
consisting of 25 mM Tris-HCl, pH 8.0 and 5 mM MgCl2. The proteins were stored at -




The concentrations of the proteins were quantified by using the Bradford protein 
assay using Bovine serum albumin (BSA) as standard. The amount of Coomassie 
Brilliant Blue dye bounded to the BSA standards and the unknown protein was 
measured at 595 nm using the Thermo VarioskanTM after incubation at room 
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temperature for 15 min. The processing of the data was done using Thermo 
VarioskanTM Skanit software.  
 
3.6.5 Hydrolytic Activity assay of the mutants  
All the activity assays with the mutated enzymes were conducted with two different 
substrates, p-nitrophenyl α-N-acetyl-D-glucosaminide (pNP-α-GlcNAc) and o-
nitrophenyl α-N-acetyl-D-glucosaminide (oNP-α-GlcNAc), by means of a microplate 
high-throughput continues spectrophotometric assay. All reactions were conducted in 
triplicate at 25oC in a finale reaction volume of 250 μL. The assays contained 2 μM 
enzyme, 100 mM sodium phosphate buffer, pH 7.3, and with a range of substrate 
concentrations varying from 0-2.5 mM. The liberation of the p-nitrophenyl and o-
nitrophenyl was monitored at 400 nm for 10 minutes. The rates were calculated using 
linear regression curve and the Michealis-Mention parameters determined. The 
extinction coefficient of ɛ = 13.3 mM-1.cm-1 for p-nitrophenyl and ɛ = 1.8 mM-1.cm-1 for 
o-nitrophenyl was used to calculate the concentrations using the Beer-Lambert law. 
3.6.6 Evaluation of the thermal stability of α-N-acetlyglucosaminidase 
and its mutants 
CD spectroscopy and thermal analysis was conducted using a Photophysics 
Chirascaw-plus spectrometer. The samples contained 0.5 mg/mL protein in Tris 
buffer (25 mM Tris-HCl, pH 8 and 5 mM MgCl2. The optimum wavelength for analysis 
of thermal stability was determined by a CD scan from 200-300 nm at 25oC and the 
thermal stability experiments was conducted by heating the samples from 25oC to 
100oC and following the denaturation of the protein at 220nm. 
 
3.6.7 Evaluation of the thioglycoligase ability of the mutants 
The evaluation reactions of the thioglycoligase ability were conducted at the 
laboratory of Dr Marco Moracci at IPB-CNR in Naples, Italy.  
The three mutants described above were tested for their thioglycoligase ability 
together with other two α-N-acetylglucosaminidase mutants (CpGH89E601G and 
CpGH89E483G) provided by Dr. M. Moracci. DNP-α-GlcNAc was used as the donor 
substrate. All thioglycoligase reactions were done in 100 mM sodium phosphate 
buffer, pH 7.3, with 0.017-0.275 mg/mL enzyme and 5 mM of DNP-α-GlcNAc in a 
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final volume of 200 µl. The reactions were done in the presence and absence of 100 
mM NaN3. After incubation at 37
oC overnight, the reaction mixtures were analyses by 
thin layer chromatography (TLC) (Ethyl acetate: methanol: water, 7:2:1), visualised 
with UV light to observe the nitrophenol group and 10% sulphuric acid in methanol. 
For each reaction 4x5 μL of the solution was spotted on the TLC.  
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Chapter 4: Conclusion and future work 
4.1  Summary of results achieved  
M. tuberculosis utilizes mycothiol (MSH) as the major low molecular weight thiol to 
protect itself against oxidative stress and so doing ensure its growth and survival [1-
5]. This has led to numerous studies on the enzymes involved in the biosynthesis of 
MSH and MSH-dependent enzymes with the aim to identify potential drug targets [6]. 
The work described in this thesis focused on MshB (GlcNAc-Ins deacetylase), the 
third enzyme in the MSH biosynthesis pathway. Currently there are several practical 
factors that affect the development of inhibitory compounds against MshB, which 
includes the lack of a suitable high-throughput continuous assay to assay MshB 
activity, and the poor availability of its natural and alternative substrates. To address 
these issues two aims were set for this study. 
 
Aim 1: Investigation and characterization of known alternative substrates of 
MshB for use in the development of a new continuous assay of the enzyme 
In the course of this study three chromogenic compounds (GlcNAc-SDNP, GlcNAc-
SPNP and GlcNAc-SBn) were used as alternative substrates for MshB for the 
development of a continuous assay of its activity. Analyses with an FSA-based assay 
showed that GlcNAc-SBn is the best alternative substrate for MshB of the three 
substrates, while on the other hand a DNTB-based showed GlcNAc-SDNP to be the 
best alternative substrate. It was found that the deacetylation of GlcNAc-SDNP by 
MshB unmasks a free thiol through an S→N intramolecular rearrangement (a so-
called Smiles rearrangement) that occurs between the free amino group exposed 
after the deacetylation reaction and the dinitrophenyl group. The free thiol reacts with 
DNTB to liberate NTB, the concentration increase of which can be measured 
continuously by following the absorbance increase at λmax 412nm. Through this 
enzyme-initiated Smiles rearrangement the first continuous assay for MshB was 
developed, thereby achieving the first aim of the project. 
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Aim 2: Engineering of an α-N-acetylglucosaminidase for biocatalytic 
preparation of thioglycosides as alternative substrate of MshB  
Three new α-thioglycoligases were generated through site-directed mutagenesis of 
an α-N-acetylglucosaminidase of Clostridium perfringens (CpGH89) using SOE PCR, 
and expression using the Novagen pET™ system to give N-terminally His-tagged 
proteins that could be purified by IMAC. The generated α-thioglycoligases 
(CpGH89E483Q, CpGH89E483A and CpGH89E483S) were found to be thermally as 
stable as the parent CpGH89 glycosidase (Section 3.3.3, Figure 3.8) and were able 
to promote transglycosylation in the presence of NaN3. Furthermore, the α-
thioglycoligases displayed much reduced hydrolytic activity than the parent CpGH89 
glycosidases. However, the CpGH89E483G mutant only promoted hydrolysis even in 
the presence of NaN3 (Section 3.3.5, Figure 3.11, R3+ and R3-), and was therefore 
not found to be suitable for use as a biocatalyst. In summary, three α-thioglycoligases 
based on CpGH89 were generated, thereby achieving the second aim of the study. 
These enzymes are good candidates for the enzymatic synthesis of GlcNAc-based α-
thioglycosides.  
 
4.2  Future work 
4.2.1 Validation of α-thioglycoligases as a biocatalysts for synthesis of 
thioglycosides 
Although the ability of the α-thioglycoligases to promote the transglycosylation step 
has been confirmed, as well as the reactivity of the glycosyl-enzyme intermediate 
with the small azide nucleophile, the next important step will be to show that thiol-
containing nucleophiles can also be used in this manner. This will validate the 
biocatalysts’ α-thioglycoligase ability, and will allow their implementation in the large-
scale production of a range of MSH analogs. Future studies will therefore include the 
chemical synthesis of suitable thiosugar acceptor molecules, since these are not 
commercially available, followed by validation of the biocatalyst’s α-thioglycoligase 
ability. 
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4.2.1.1 Chemical synthesis of thiosugar acceptor molecules 
Two different thiosugar acceptor molecules will be synthesised by means of multi-
step chemical synthesis based on previously described methods, as outlined in 
Scheme 4.1 [7-9]. 
Synthesis of 4-thio-β-D-glucopyranoside (4.5): The method of Liu et al. [7] will be 
used to synthesise 1,4:3.6-dianhydro-β-D-fructofuranosyl-4-chloro-4-deoxy-α-D-
galactopyranoside (4.2), wherein compound 4.1 (sucralose) will be the starting 
material. Compounds 4.3 (4-chloro-4-deoxy-α-D-galactopyranose) and 4.4 (4-thio-β-
D-galactopyranose) will subsequently be synthesised following the method described 
by Liu et al. in 2005, and Chen, et al. in 2010,  respectively [8, 9]. 
At present compounds 4.2, 4.3 and 4.3 have already been prepared using the 
published methodology. Future work involves the up scaling of the production of 
compound 4.3, and finding conditions to perform the thioacetylation reaction to form 
compound 4.4 followed by the  removal of the acetyl group to make the desired 
compound 4.5 (4-thio-β-D-glucopyranoside).  
Synthesis of p-nitrophenyl-4-deoxy-4-thio-β-D-glucopyranoside (4.8): 
The same previously described methods will be used to make compound 4.2 and 
4.3. Compound 4.6 (p-nitrophenyl-4-deoxy-4-chloro-β-D-glucopyranoside) will then be 
synthesised following previously described methods. Compounds 4.7 (p-nitrophenyl-
4-deoxy-4-thioacetate-β-D-glucopyranoside) and 4.8 will be prepared using the same 
methodology used to prepare 4.4 and 4.5. 
At present compounds 4.2, 4.3 and 4.3 have already been produced using the 
published methodology. Future work involves up scaling the production of compound 
4.3, synthesis of compound 4.6, and conversion of it to compound 4.7 and compound 
4.8 (p-nitrophenol-1,4-dithio-β-D-glucopyranoside).  
 































































Scheme 4.1: The reagents and condition for the chemical synthesis of the different 
thiosugar acceptor molecules: (a) 0.5 M of compound 4.1 in 100 mL H2O, 3.5 M of 
KOH in 50 mL H2O, 55
0C, 4h; (b) H2SO4 (0.4 mL), 0.25 M of compound 4.2 in 40 mL 
H2O, 60
0C; (c1) 5g of compound 4.3, 105 mL of DMPU (1,3-dimethyl-3,4,5,6-tetra-
hydro-2(1H)-pyrimidinone), 8.6 g KSAc, 1.5h, RT; (c2) 0.5g of compound 4.3, 0.5g of 
p-nitrophenol, 15 mL anhydrous CH2Cl2, 1g 4 Å molecular sieves, 50 μl of BF3.Et2O, 
1 mL of Et3N, 3h, 30
0C, (d) Same as c1, except that the starting material is 
compound 4.6. 
 
4.2.1.2 Validation of the biocatalyst’s α-thioglycoligase ability and the 
implementation of the new α-thioglycoligase created for large-scale production 
of a range of MSH analogs. 
The biocatalytic preparation of α-thioglycosides will be done using the approach 
described in Section 3.2.4, Figure 3.5. The enzymatic reaction products will be 
purified by preparatory TLC and analyzed by NMR and LC-MS. These synthesized 
analogs will be evaluated as alternative substrates of MshB using both the 
discontinuous and continuous assay for MshB described in Chapter 2. In addition, 
the compounds will also be tested as alternative substrates or potential inhibitors 
against the other MSH biosynthesis pathway. 
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4.2.2 Investigation of α-glycosynthases as biocatalysts  
As stated in Section 3.2, two options exist for the generation of a biocatalyst that will 
enable synthesis of natural or alternative substrates for MshB in large quantity. For 
this study, Option 2, namely the use of a thioglycoligase strategy, was investigated 
as reported in Chapter 3. However, during the course of this study, investigations in 
the use Option 1, which is based on the use of glycosynthases as biocatalysts, were 
initiated by our collaborator (Dr. M. Moracci, IPB, Naples, Italy). His group generated 
three potential α-glycosynthases, CpGH89E601G, CpGH89E601A and 
CpGH89E601S, from the α-N-acetylglucosaminidase of Clostridium perfringens 
(CpGH89) by mutating the nucleophilic catalytic active residue Glu601 to Gly, Ala 
and Ser through site-directed mutagenesis. As part of our on-going collaboration with 
his group, these mutants were tested for thermal stability. Only CpGH89E601G was 
found to be thermally as stable as the wild type, while the other two mutants were 
less stable than the wild type. CpGH89E601G also demonstrated reactivation by an 
external nucleophile (NaN3) in reactions analysed by TLC. However, it was also 
found to promote hydrolysis activity in absence of an external nucleophile (Samples 
R2+ and R2-, Figure 3.11). This was quite surprising as one would expect hydrolysis 
activity to occur only in the presence of an external nucleophile that can mimic the 
activity of the mutated active site nucleophile residue. This indicates that there might 
be another unidentified nucleophile in the active site, or that the mutation caused a 
rearrangement in the active site that changed the chemical roles of the active site 
residues.  
Future studies, which will be performed in collaboration with Dr. Moracci, will involve 
identification of this nucleophile and evaluation of the α-glycosynthase ability of this 
enzyme for use in the biosynthesis of MSH and its analogs using the approach 
described in Section 3.2.4.  
 
4.3 Conclusion 
The development of the first high-throughput continuous assay of MshB should have 
a significant positive effect on the on-going drug development studies that target this 
enzyme, and may allow the identification of a suitable MshB inhibitor with 
antituberculosis properties. Furthermore, the preparation of thioglycoligase and 
glycosynthase biocatalysts based on the α-N-acetylglucosaminidase from C. 
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perfringens could enhance the availability of the MSH biosynthetic intermediates and 
perhaps MSH itself, as this will allow their preparation through enzymatic synthesis 
without the need for the protection and deprotection of the other functional groups as 
would be required in chemical synthesis. Thus far, the prepared thioglycoligases 
have been revealed to be good candidates for the preparation of GlcNAc-based 
thioglycoside molecules which can be used as either alternative substrates or 
inhibitors of MSH biosynthetic enzyme – especially MshB – and other MSH-
dependent enzymes. While this may solve the problem of synthesizing MSH and it 
analogs, such a strategy will still require the production of the substrate donor and 
substrate acceptor molecules that are required for the enzymatic synthesis reactions. 
However, since the synthesis of these molecules are significantly simpler than that of 
MSH and its biosynthetic intermediates, the biocatalytic preparation method is still an 
important improvement of the current situation, and should enhance the availability of 
these molecules for antituberculosis drug development that target MSH biosynthesis. 
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Addendum A 
Supplementary Information for the OBC publication (reproduced in Chapter 2) 
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LC-HRMS: Base peak ion chromatograms 
For samples prepared with TCEP added: 
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For samples prepared without added TCEP: 
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Mass spectra extracted from chromatograms: 
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NMR Spectra: 
4-Nitrophenyl 2-acetamido-2-deoxy-1-thio-α-D-glucopyranose (3a) 
1H NMR (300 MHz, CD3OD): 
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.0
 2.0  2.1 
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2,4-Dinitrophenyl 2-acetamido-2-deoxy-1-thio-α-D-gluco-pyranose (3b) 
1H NMR (300 MHz, (CD3)2SO2): 
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Benzyl 2-acetamido-2-deoxy-1-thio-α-D-glucopyranose (3c) 
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